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                                                                   Abstract 
Tuberculosis (TB) and human immunodeficiency virus (HIV) are difficult conditions to 
manage, in tandem they pose even more challenges to public health programs in 
identifying coinfection to ensure that all TB cases are treated to completion of therapy 
(COT). The purpose of this study was to test variables that predicted COT among the 
HIV/TB coinfected population of non-Hispanic, U.S.-born Blacks alive at the time of 
diagnosis. Social determinants of health were the theoretical foundation used to guide the 
study based on data from the Report of Verified Cases of TB (RVCT) between 2009 and 
2014. Relationships were tested between ethnic/racial group membership and the 
likelihood of COT, and whether any association to COT was moderated by COT 
eligibility; a Centers for Disease Control and Prevention calculated algorithm considering 
disease severity, site, age, and disease complexity. The research design was a longitudinal 
quantitative approach using binary logistic regression to identify correlated variables 
associated with COT in the final model. The results showed no statistically significant 
differences   among racial/ethnic groups, age, and gender for COT. COT was moderated 
by COT eligibility; odds ratio (5.4 - 11.6) times more likely to complete therapy.  This 
study supports positive social change for programs by providing data driven outcomes to 
providers that support outreach, patient education, and disease prevention. In addition, 
this research describes an evaluation metric based on performance to set a foundation for 
collaboration among partners who manage other comorbidities in the United States.  
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Chapter 1: Introduction to the Study 
Background of the Study 
Tuberculosis (TB) accounts for 9.4 million cases worldwide and is the leading cause of 
death by an infectious agent. Most of the reported cases come from Sub-Saharan Africa and 
areas of Europe driven by the human immunodeficiency virus (HIV) epidemic (Getahun, 
Gunneberg, Granich, & Nunn, 2010). The epidemiology of HIV infection begins with more than 
33 million persons infected. Two-thirds of this population lives in Sub-Saharan Africa, and 80 
percent of all HIV infections are sexually transmitted. Coinfection estimates are 30 percent of 
HIV-infected persons usually diagnosed with latent tuberculosis infection (LTBI) (Getahun et 
al., 2010).  
The risk of exposure to TB is the same for all persons who are in close contact with a 
person that has the active disease; the problem is that risk factors increase for those who have 
pre-existing medical conditions. Also, episodes of homelessness, IV drug users, working in 
congregate settings such as churches, jails, drug treatment centers, and those who have immune-
suppression conditions such as HIV also increase risk (Centers for Disease Control [CDC], 
2014a).  TB detection through by administering a tuberculin skin test or IGRA blood test helps 
practitioners in diagnosis; if positive, additional tests to include an x-ray should be performed to 
determine in TB infection has progressed to disease. Clinical presentations of TB and HIV 
infection accentuates the progression of the other resulting in compromised immune situation 




             
Understanding the epidemiology of HIV and TB disease specifically and in tandem is a 
critical construct of this project because environmental situations and the many platforms in 
which disease propagates makes interventions very difficult to design and very expensive (CDC, 
2014a). Clarity in understanding how each variable interacts concerning completion of therapy 
could help practitioners focus limited resources efficiently by addressing variables significant to 
completion of therapy.  
Alternatively, understanding those interactions that may not be as significant can is 
crucial in the redirection of funds, resources, and services. Program Collaboration & Services 
Integration (PCSI) may provide a framework for intervention implementation with the least 
amount time and resources. The CDC recommends such collaborations in their 2016 guidelines 
for improving programmatic standards of care (Sotgui et al., 2016).  
 In 1882, Dr. Robert Koch announced Mycobacterium Tuberculosis (MTB) as the cause 
of TB which was responsible for the deaths of one out of seven people in the United States and 
Europe (CDC, 2014a). In the more than 100 years since the discovery, TB has peaked since the 
1960s and declined in recent years. During this time there has been a much-publicized decrease 
in active cases which has provided a false sense of security among Americans (CDC, 2014a).  
In 1981, HIV detection and diagnosis began the clinical awareness in a gay man through 
the treatment of Kaposi’s sarcoma, a rare form of cancer. In 1982, acquired immune deficiency 
syndrome (AIDS) caused by HIV infection began the era of the HIV/AIDS epidemic in the 
United States, which developed into one of the most resource-dependent health initiatives to date 
(CDC, 2014a). Both TB and HIV/AIDS are caused by microscopic organisms, bacteria and 
virus, respectively. Bacteria, viruses, parasites, and fungi are infectious disease organisms that 
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cause medical disorders and are the most common organisms that cause illnesses (WHO, 2014b). 
Many of these organisms live in the body and remain harmless to the individual and go 
unnoticed. Some unnoticed bacterial known as normal flora and serve as a benefit the body.  
Other organisms can cause disease, and those disorders are among the reasons why health 
care is required (Mayo Clinic, 2014). Disease-causing microorganisms are often infectious, and 
transmission is an insect, animal bite, or other vectors. Some organisms may be passed from 
person to person through the air, water, or injection (CDC, 2014b). Signs and symptoms of 
infection or disease often include fever and fatigue (CDC, 2014b). Preventive vaccines help fight 
the spread and damage of several diseases causing organisms and protect the public from 
outbreaks.  
For example, chickenpox, measles, and influenza all have vaccines that are accessible by 
most public health agencies and for distribution by the community (WHO, 2014b). TB is an 
organism that may cause degradation of the body or death if untreated (CDC, 2014b). 
Vaccination is not currently available as a preventive measure for TB (CDC, 2014b).  HIV is one 
of the most culturally common nomenclatures to date; it can also lead to medical complications 
such as acquired immune AIDS or death (CDC, 2014a).  MTB is spread from person to person 
through the air usually affecting the lungs. It may also impact other parts of the body such as the 
brain, kidneys, and lymph nodes depending on the site of infection (CDC, 2014a).  
Signs and symptoms of TB vary significantly. Persons with TB often complain of a 
cough, chest pain, weight loss, and general malaise (CDC, 2014a). HIV has similar signs and 
symptoms of TB.  HIV infected persons may complain of night sweats, weight loss, and general 
malaise which can make a speedy diagnosis difficult for practitioners because TB signs and 
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symptoms mimic several other illnesses and carry the moniker “the great imitator” (CDC, 
2014a). The critical transmission factors for HIV are sexual intercourse or intravenous (IV) drug 
use in contrast to an airborne person to person transmission of TB (CDC, 2014a; Metcalf et al., 
2014;).  
Completion of therapy (COT) characteristics of Non-Hispanic Blacks with TB and HIV 
is one of several public health concerns for high-risk populations. TB and HIV are among the 
preventable conditions that have sparked collaborations with other countries and international 
partners in controlling the transmission and spread of TB and HIV respectively (CDC, 2014b). 
The National TB Control Program managed by the CDC has a mission to promote health and 
quality of life by preventing, controlling, and eventually eliminating infectious diseases such as 
TB in the United States (CDC, 2014b).  
Global TB control is facing severe challenges in delivering the quality of care assessable 
to all persons regardless of barriers such as gender, age, and type of disease, social setting, and 
the ability to pay (WHO, 2014a). This study is needed because coinfection with TB and HIV 
makes domestic and international control activities very complex and demanding for keeping 
communities safe. These challenges must be addressed by national programs to focus on 
individually tailored approaches that address demographic trends and individual needs (WHO, 
2014b).  
The effects of understanding completion of therapy for non-Hispanic Blacks may 
improve outcomes through understanding variables associated with both positive and negative 
results. Understanding variables may produce positive social change by decreasing the incidence 
disparities among this population as well as decreasing overall TB transmission because 
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completion increases the cure probability of TB and dramatically reduces the transmission and 
the development of new cases and the potential for developing multi-drug resistant (MDR) forms 
of tuberculosis (CDC, 2014a). Significant sections of discussion for this chapter will include TB 
and HIV background, problem statement, research question and hypothesis, the purpose of the 
study, theoretical framework, terms and definitions, assumptions, limitations, the significance of 
the review, summary, and discussion.  
Background 
Before the 1960s, TB was one of the most significant causes of death in the world, but 
the development of tuberculosis drugs reduced prevalence in the United States resulting in a 
level of TB control (WHO, 2014c). Based on resources, funding, laboratory diagnostics, and 
expertise, countries of high prevalence were not able to control TB well which resulted in the 
development of MDR and extensively drug-resistant (XDR) TB cases. All forms of TB 
ultimately complicate treatment regimens in persons with HIV and increases their chances of 
adverse outcomes (WHO, 2014c).  To address the severe problem associated with drug-resistant 
strains of TB, the CDC developed recommendations that all people newly diagnosed with HIV 
should be tested for TB as soon as possible.   
The CDC recommends testing because HIV positive persons face a significant risk of 
progressing to TB disease if they exposed to MTB (CDC, 2014b). Although HIV-related TB is 
treatable and preventable, incidence rates continued to climb because resources are limited which 
ensure screening, testing, treatment regimens are started (CDC, 2014a). Drug interactions for 
overlapping medication toxicities and immune system inflammation further complicate treatment 
outcomes and completion of therapy. Sub-Saharan Africa has the highest incidence of 
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coinfection in the world accounting for 79 percent of all reported cases (WHO, 2014c). The rest 
of the world accounts for the remaining 21 of coinfections.  
The WHO first reported TB as a world health problem in 1993 and implemented 
recommendations and strategies to incorporate directly observed therapy short-course (DOTS) as 
the best technique for managing TB. Directly observed therapy short-course consist of a health 
care representative watching patients under treatment ingest each dose of recommended therapy 
to ensure COT has been met (Bekker & Wood, 2010; CDC, 2014a; WHO, 2014a;). Although 
HIV testing is the recommendation for persons with active TB, compliance is reduced even in 
developed countries, resulting in the missed diagnosis of symptoms and providers failure to 
identify risk factors for HIV transmission (WHO, 2014b).   
Kwan and Ernst (2011) stated the intersection between TB and HIV have deadly 
consequences and require robust interventions; without adequate TB control, the Healthy People 
2050 target for TB elimination will not occur. The history of coinfection throughout the world is 
apparent, but coinfection in the United States does not have the overall research for the national 
TB program to provide a standard template that addresses comorbidities (Kwan & Ernst, 2011). 
Despite advances in medicine and overall health care, TB and HIV are collectively a powerful 
health concerns that remain a consistent challenge for public health programs and private 
providers to manage screening, testing, treatment regimens, care plans, and preventive activities 
(CDC, 2014a; WHO, 2014c).  
Considering the complex nature of both TB and HIV diagnosis and treatment, public 
health officials have labeled the presence of both conditions as coinfection or comorbidities and 
have outlined several interventions that address both conditions through a protocol to increase 
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the chances of a positive outcome (CDC, 2014a). In 2014, the CDC reported 9,412 cases of TB 
in the United States that included cases from all 50 states and the District of Columbia (DC) and 
developed a public health message that TB is still alive and relevant in the country (Alami et al., 
2014). In 2014 the CDC also reported an incident rate of 3.0 per 100,000 persons as a significant 
decrease compared to rates of 5.2% published in 2013 (CDC, 2014a).   
Overall TB rates have declined since 1993 to the lowest rates in recorded history, but 
Asians, Hispanics, and Non-Hispanic Blacks represented the most significant proportion of 
disease disparity (Alami et al., 2014; CDC TB, 2014a; WHO TB, 2014a;). Disease burden 
among foreign-born persons in 2014 was 65% of the total reported cases (Alami et al., 2014, p. 
35).  In 2013, HIV status and test results were published for 88% of all reported TB cases in the 
United States. Seven percent or 543 persons with TB disease tested positive for HIV (CDC, 
2013a). The CDC stated that progress had been made to close the gap among racial, ethnic 
minorities, and foreign-born persons, but they remain the groups disproportionately affected by 
TB.  
TB is the number one cause of death among persons with HIV and the most common 
presenting illness accounting for more than 360,000 deaths in 2014 (WHO, 2014a). Persons 
living with HIV also have an increased burden of drug-resistance if their TB diagnosis is delayed 
(Alami et al., 2014). To complicate their situation further, multidrug-resistant (MDR) and 
extensively drug-resistant (XDR) TB places an extraordinary clinical and mental burden on 
persons living with HIV (Alami et al., 2014; CDC, 2014a; WHO, 2014a;). In 1985, the United 
States Department of Health and Human Services (USDHHS) published the Heckler Report 
which documented health disparities among racial and ethnic minorities in the United States.  
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As a partial response to this publication, in 2010, the Affordable Care Act (ACA) 
reauthorized the Office of Minority Health to improve the health of racial and ethnic minorities 
through the development of health policies, programs, and interventions (HHS OMH, 2014).  
The USHHS action plan uses the ACA foundation and initiatives such as Healthy People 
2020, Let's Move First Lady Project, and the national HIV/AIDS strategy to energize their action 
plan into real-life interventions.  Knowing HIV status of TB patients is a significant part of the 
CDC treatment and care recommendations.  
Providers can determine treatment regimens and referrals to coordinate with other 
services to provide an integrated care plan to ensure completion of treatment and improve quality 
of life (QOL) (CDC, 2007). Pascopella et al., (2014) described frequencies and attributed 
analysis of TB testing and treatment in four Ryan White HIV clinics to highlight the importance 
of knowing TB status among HIV patients in their cross-sectional study of policies and practices.  
This study complied with the Revised Recommendations for HIV Testing of Adults, 
Adolescents, and Pregnant Women in Health-Care Settings (2006). The lack of peer-reviewed 
studies that link advanced analysis to specific variables associated with completion of therapy 
among non-Hispanic Blacks is the gap in the literature that researchers recommend further 
empirical research is required (Abraham, Winston, Magee, & Miramontes, 2013). Over the past 
five years research has begun to address the gap in the literature concerning comorbidities among 
persons with TB. The primary reason why the investigation stalled is due to the high cost of 
treatment and care as well as having a surveillance methodology to support data (Chindelevitch 
et al., 2015).  
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Current literature reviews describe three studies related to coinfection, with only one U.S. 
study highlighting TB and HIV. Rodwell et al., (2010) used longitudinal surveillance data to test 
associations between TB and HIV coinfection and sociodemographic risk factors with 
polychotomous logistic regression. This is a sentinel study, very resource dependent, which 
began the inquiry towards identifying the completion of therapy variable as a covariate.  
Understanding components of coinfection where completion of therapy is the dependent 
variable are not approached in previous studies. This study intends to shorten the current gap in 
the literature and provide a useful tool that could help identify variables associated with non-
Hispanic Blacks and identify other high risk ethnic and racial groups to help providers develop 
interventions for these populations as described in 2016 CDC recommendations (CDC, 2014a). 
Problem Statement 
TB transmission among high-risk persons including Non-Hispanic Blacks is an 
increasing problem for screening, testing, treatment, and the completion of therapy in the United 
States.  Treatment complexity, as well as reductions in funding, has weakened local TB control 
program's overall effectiveness to reduce health inequities (CDC, 2014a). Unknown HIV status 
makes completion of therapy and TB cure very challenging, expensive, and uncertain (CDC, 
2013b). Collectively, TB and HIV/AIDS coinfection places an individual at higher risk for poor 
health, morbidity, and mortality (CDC, 2014a). National TB control statistics publication in 2007 
for the years (1993-2005) only provide descriptive aggregated data analysis and does not address 
COT as the dependent variable (CDC, 2007a).  
 In the 2007 CDC publication researchers described a disproportionately high rate of TB 
among non-Hispanic Blacks as compared to non-Hispanic Whites. Decreases in local funding 
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have affected many TB programs abilities to ensure completion of therapy for persons with TB. 
The CDC suggests that program effectiveness is directly related to losses in resources such as 
incentives and enablers which have placed a significant burden on local and state programs to 
address their high-risk populations.  
Also, decreases in programmatic capacity based on the same limited resources pose 
additional barriers for the management of TB cases. Effective case management is an essential 
resource for reducing incidence and prevalence rates among this population (CDC, 2014a). 
Increased case rates have prompted the CDC to support programs to employ creative public 
health initiatives that address the disproportionate rise and increases in urban TB outbreaks 
(CDC, 2014a). Coinfection requires that individuals receive specialized care and treatment 
regimens that include systematic program collaboration and service integration (PCSI) by 
community partners to maintain the continuity of care, and ensure the medical outcome is COT 
(CDC, 2014a).  
Purpose of the Study 
This study is a quantitative analysis of systematic data collected by the CDC Division of 
TB Elimination (DTBE) National TB Surveillance System (NTSS). It focuses on comparing 
associations and correlations of variables associated with completion of therapy for Report of 
Verified Cases of Tuberculosis (RVCT) identified racial/ethnic groups with TB and HIV 
focusing on non-Hispanic Blacks in the United States. By using advanced logistic regression 
analysis, I hope to identify factors that may correlate to an individual's ability to complete 
treatment for TB, which results in increase QOL. Aggregated data from the RVCT (2009-2014) 
database may provide the subject matter to fill the gap identified by the most recent studies.  
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            Both descriptive and advanced studies could provide health care practitioners with data-
driven evidence that helps foster initiatives and interventions (CDC, 2014b). Interventions 
subsequently may be used to stop disease transmission and intervene against disease propagation 
and degradation of health. Correlations and associations could provide a foundation for 
understanding individual variables that place race/ethnic groups at a higher risk for coinfection 
and not completing treatment. This project has the potential to impact and affect positive social 
change by providing public health practitioners variables that are significant to completion of 
therapy which may be used to improve the QOL and raise the standards of care offered by TB 
control programs. Increasing the probability of cure through disease intervention may improve 
health outcomes as well as address population health determinants.  
          Coinfection initiatives in Africa have addressed the burden and impact of HIV treatment 
on the weight of TB programs (Chindelevitch et al., 2015). Researchers in Scotland performed a 
longitudinal study describing risk factors for persons with HIV based on increased risk of 
developing TB, new infections, and reactivation of latent TB (McDonald, Smith-Palmer, 
Wallace, & Blatchford, 2015). One U.S.-based California study (Metcalf, 2013) began to cross-
match incident TB cases reported in surveillance systems with HIV registries to compare 
characteristics of patients with coinfection for mortality and complications of persons not on 
antiretroviral therapy. Rodwell et al. (2010) sought to understand TB and HIV coinfection trends 
in San Diego County to identify associations between sociodemographic risk factors and TB and 
HIV coinfection.  
          In each study, researchers recognized the significance that comorbidities have of patient 
outcomes and the importance of surveillance and resource management, and expertise required 
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to improve outcomes.  Comorbidity has been defined by the CDC as an emerging priority of 
program collaboration to meet the needs of at-risk populations (CDC, 2014c).  Prussing et al. 
(2015) described coinfection among persons with HIV and viral hepatitis as another high-risk 
population within the New York City population that requires further investigation to develop 
interventions as defined by CDC for creative initiatives. Marks et al. (2011) published a critical 
study that examined the trends and risk factors associated with TB mortality to help pinpoint 
intervention opportunities. This study focused on the HIV variable regarding death which 
provided an excellent foundation for coinfection research.   
In the past five years, researchers have begun to develop studies aimed at comorbidities, 
but the main factors that prevent local public health agencies from performing necessary data 
collection are lack of funding (CDC, 2014a; WHO, 2014c). In each study discussed, researchers 
agreed that more analysis that describes comorbidities were required to help develop strategies 
within high-risk communities that help practitioners better manage high incidence of cases. The 
CDC recommends that treatment completion for all persons with TB disease, LTBI, and 
coinfection among high-risk populations should be the highest priority for TB Control programs 
for testing, screening, and treatment in the United States (CDC, 2014c).   
Rodwell et al. (2010) performed a study evaluating disparities in disease burden in 
Southern California to understand TB and HIV coinfection trends in San Diego County because 
they recognized the importance and symbiotic nature of both conditions. The Rodwell et al. 
(2010) study is only one of a few that asks and addressed several of questions that surround 
comorbidities of two health conditions. Briggs et al. (2015) and Chindelevitch et al. (2015) 
discussed program collaboration among TB and HIV programs and literature reviews for 
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prophylactic treatment regimens respectively, but neither addressed completion of therapy 
characteristics among high-risk persons to include minorities.  
Researchers are beginning to place more emphasis on evaluating the potential impact of 
HIV treatment with integrated tuberculosis control programs on the overall burden of coinfection 
(Chindelevitch et al., 2015). Treatment complexity as well as reductions in funding, have 
weakened the overall effectiveness of local TB control programs to reduce health inequities 
among all persons at risk to include Non-Hispanic Blacks (CDC, 2014a).  
Unknown HIV status can affect completion of therapy outcomes for TB and result in a 
less than adequate management plan for the patient, resulting in prolonged challenging treatment 
regimens, excessive costs, and uncertain outcomes (CDC, 2013a). Collectively, TB and HIV 
infection and AIDS places an individual at higher risk for morbidity, mortality, and degradation 
of health (CDC, 2013). National TB control statistics last published in 2007 for the years (1993-
2005) show ethnic disparities through fundamental statistical analysis. Researchers only 
provided a descriptive analysis of these data which does not reflect inferences towards 
understanding why Non-Hispanic blacks are in a higher risk group (Alami et al., 2014).  
 There are disproportionately high rates of TB among non-Hispanic Blacks and foreign-
born persons in the US. The description does not include completion of therapy effectiveness. 
Decreases in local programmatic funding magnify the importance of analysis to understand 
associations and inferences. Also, said funding has shown to decrease programmatic capacity to 
manage cases which is a crucial indicator for higher incidence and prevalence rates among this 
population based on incomplete contact investigations, staffing, and expertise (CDC, 2014a).  
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Disproportionate case rates among minorities have prompted the CDC to promote and 
support programs that employ creative public health initiatives to address rises in metropolitan 
TB cases and outbreaks (CDC, 2014c). Coinfection identified in a TB case or an outbreak 
requires an individual to receive specialized care and treatment regimens that include PCSI to 
maintain a continuity of care. A PCSI program helps community partners facilitate a consistent 
network of care where completion of therapy can be reached and maintained for all populations 
(CDC, 2014c).  
The lack of peer-reviewed studies that link advanced analysis to specific variables 
associated with coinfection and completion of therapy among non-Hispanic Blacks is a 
significant gap in the literature, and my research may provide insight into data trends that support 
the development of community-based initiatives that are designed to reduce case rates and 
transmission of TB. Through the dissemination of findings, this study may provide leverage to 
the field of public health to create changes in policy that reduce health disparities. 
 The overall focus of my project is to identify relationships among variables available in 
the RVCT 2007 tool and make data open to the public health community that may influence 
social change as well as policy. The analysis of variables outlined and reported in the RVCT and 
described in the Annual Report of TB in the United States surveillance updated but reports are 
limited to aggregated descriptive components and frequencies to characterize populations.  
Data reported in the RVCT consists of the mostly dichotomous variable which is 
appropriate for multiple regression analysis (Plichta, Kelvin, & Munro, 2013). The variables I 
chose to examine will be expanded to include dependent variable = completion of therapy; 
independent variables = HIV status and TB disease; covariates = age, gender, HIV status, 
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homelessness. Also, injection drug use, alcohol use, occupation, the resident of a correctional 
facility healthcare provides the type, multidrug-resistance, noninjecting drug use, disease site, 
previous TB, sputum culture finding, sputum smear finding, chest x-ray finding, status at 
diagnosis, directly observed therapy, and completion of therapy.  
The standard variables discussed support all demographic, clinical, diagnostic, disease 
and treatment history components of this study. Early diagnosis and timely comprehensive 
treatment of persons living with HIV and TB are critical components to reducing TB related 
mortality (WHO, 2014a). Both CDC and WHO recommend screening for active TB among the 5 
million persons living with HIV throughout the world.  
Considering the gravity and complexity of diagnosis, treatment, and care, the overarching 
focus of this project is to identify characteristics of completion of therapy among coinfected 
Non-Hispanic Blacks in the United States. This study employed a longitudinal quantitative 
design to analyze secondary data for each person diagnosed with TB who has a documented HIV 
positive status. The dataset resides at the CDC in Atlanta in the National TB Surveillance System 
dated 2009-2014.  
Data analysis will include all verified cases of TB among a subset for Non-Hispanic 
Blacks with HIV. The data collection design is a nonexperimental observational platform that 
will involve a systematic analysis of RVCT data to identify relationships, behavioral factors, and 






             
Research Questions 
Research Question 1: What is the relationship between and individual’s ethnic/racial 
group membership among U.S.-born non-Hispanics with an HIVTB co-infection and the 
likelihood of completion of therapy?  
H01: There is no relationship between individual’s ethnic/racial group membership 
among U.S.-born non-Hispanics co-infected with HIV/TB and the likelihood of completion of 
therapy.  
Ha1: There is a relationship between individual’s ethnic/racial group membership among 
U.S.-born non-Hispanics co-infected with HIV/TB and the likelihood of completion of therapy. 
Research Question 2: Is there a relationship/association for completing therapy among 
TB/HIV co-infected U.S.-born non-Hispanics with an HIV/TB co-infection moderated by 
completion of therapy eligibility?    
Ho1: There is a relationship/association for completing therapy among TB/HIV co-
infected U.S.-born non-Hispanics with an HIV/TB co-infection moderated by completion of 
therapy eligibility.   
Ha2: There is relationship/association for completing therapy among TB/HIV co-infected 
U.S.-born non-Hispanics with an HIV/TB co-infection moderated by completion of therapy 
eligibility. 
Theoretical Framework 
           Constructs from SDOH help provide and support the framework to establish conditions 
through relationships, demographics, workplace, risk factors and states that affect the quality of 
life of an individual (Glanz, Rimer, & Viswanath, 2008). The theoretical framework for 
17 
 
             
understanding relationships and impact of population groups for completion of therapy of a 
prescribed TB regimen for HIV positive non-Hispanic Blacks require a longitudinal data 
collection, extrapolation, and advanced analysis techniques to provide the best opportunity of 
understanding relationships and inferences.  
The SDOH (Glanz et al., 2008; Wilkinson & Marmot, 2003). The SDOH framework 
focuses on quantitative data collection and analysis of secondary aggregated National 
Surveillance System data. Data variables for (HIV status, age, gender, housing status, substance 
abuse, homelessness, unemployment, demographics, diagnostic status, and previous history of 
treatment) are four essential components of the model and were evaluated for fit. Policymaking: 
local, state, and federal initiative to support collaboration among programs through funding and 
guidance to affect both individual and population health us vital to align resources and services. 
Public health and private providers such as CDC and WHO publish recommendations for 
programmatic activities that provide a roadmap to meet national objectives and goals for disease 
intervention.  
Social factors, and physical conditions affect COT and is the framework for SDOH. 
Factors in which the population of concern is born, and lives all affect the QOL and outcomes in 
the public health model. Outcome variables described in the RVCT dataset for (age, gender, HIV 
status, homelessness, injection drug use, alcohol use, occupation, a resident of a correctional 
facility and type of healthcare provider) all contribute to overall health and were collected to 
evaluate COT. Clinical variables that contribute to the final disposition intended to improve the 
individual QOL are (multidrug-resistance, noninjecting drug use, disease site, previous TB, 
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sputum culture finding, sputum smear finding, chest x-ray finding, status at diagnosis, directly 
observed therapy and completion of therapy) and are important to understand associations.  
Access to health services at public health and private clinics is influenced by barriers 
such as language, availability, costs, education, and preventive care. The study challenges 
programmatic activities and resources through analysis that identify variable associations that 
can be used to reverse-engineer an existing program to deliver the outcomes necessary to address 
coinfection. The result of intervention implementation and social change is directly related to 
SDOH core constructs. Individual behavior can play a significant role in health outcomes. 
Persons lost to follow-up, refused treatment, died, moved, or have a disposition as other fall 
under the completion of therapy subset of variables. The study will provide limited behavioral 
statistics because the researcher will not interview patients.  
Secondary data analysis does offer the completion of therapy variable which suggests a 
relationship with the patient's ability to interact with their care plan. Biology and genetic factors 
affect specific populations such as age, sex, race, and HIV status.  One of the most critical 
sections of the analysis design is trying to establish a connection related to individual 
characteristics. Do women and men have the same odds of completing therapy versus 
subpopulation of older adults? This study challenges the ideals of SDOH regarding how 
variables relate to behavior centered on completion of therapy.  
The SDOH frame is an intervention theme which helps the practitioner identify variables 
linked to the RVCT database for disease interaction, intervention, and disruption of transmission. 
Each component described in the SDOH model outlined is an essential variable for consideration 
for evaluating the efficacy of public health intervention and programmatic activities (CDC, 
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2014c). The CDC has published studies that outline SDOH and health inequities as core 
guidance for co-morbidity activities among public health agencies and the private community. 
This framework will guide my design by showing graphics and narrative representations that 
help clarify the analysis process to challenge each research question.  
Nature of the Study 
A longitudinal quantitative design was used to analyze secondary data for a person 
diagnosed with TB with a documented HIV status in the United States. The dataset resides at the 
CDC in Atlanta in the National TB Surveillance System dated 2009-2014. Data analysis will be 
designed to include all verified cases of TB as well as a subset for non-Hispanic Blacks. The 
study design consisted of a non-experimental observational platform that will employ data 
collection of the RVCT with HIV status to identify relationships, behavioral factors, and relative 
risks for COT among Non-Hispanic Blacks in the United States.  
The rationale for the study depends on obtaining an accurate estimate of the relationships 
between variables (Creswell, 2009). The longitudinal platform helped describe a point in time 
relationship where completion of therapy interacts with other covariates surrounding TB cases in 
the United States. Ideally, the quantitative investigation should identify cause and effect 
relationships between variables. Secondary data does not support cause and effect outcomes but 
does support correlations and associations that are displayed in odds ratios to describe how 
strongly the presences or absence of a variable associated with the presences or absence of a 
covariate (Scotia, 2010).  
The primary source of data and information resided in the Division of TB Elimination 
CDC Atlanta National Surveillance System RVCT database. The dataset was in the form of 
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aggregated variables collected between 2009 and 2014 for all confirmed TB cases in the U.S. 
Data collection and analysis from 62 federally funded TB programs that report directly through 
their local surveillance systems to the NTSS in Atlanta Georgia for analysis. An Excel data 
requested initiated the process through an analysis plan to receive approval from CDC. The data 
was analyzed through the logistic regression methods to include fit of (t test, one-way analysis of 
variance ANOVA, F tests, linear regression, contingency tables, and Kaplan-Meier curves).   
Each record was satisfied by the Health Insurance Portability and Accountability Act 
(HIPPA) definition of confidentiality with de-identified outcome variables. Demographic 
variables for age, gender, HIV status, homelessness, injection drug use, alcohol use, occupation 
satisfies the first group of analysis. The second group of variables for a medical condition, the 
resident of a correctional facility healthcare provides the type, multidrug-resistance, non-
injection drug use, disease site, previous TB, sputum culture finding, sputum smear finding, 
chest x-ray finding, status at diagnosis, directly observed therapy, and completion of therapy to 
complete the analysis.  
Variable Descriptions 
The dependent variable of interest was COT, and the independent variables of interest are 
TB and HIV status framed under SDOH.  
HIV status: laboratory confirmation (negative, positive, indeterminate, refused, not 
offered, unknown.  
COT: bivariate, yes/no patient completed therapy within one year. (DHHS, 2014).  
Age: categorical variable, broken down in years (0-4, 5-14, 15-24, 25-44, 45-64, 65+). 
Gender: bivariate, gender of patient at birth.  
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Injection drug use: bivariate, the patient has NOT injected illegal drugs within the past 12 
months.  
Non-injection drug use: bivariate, the patient has/has not used non-injecting drugs within 
the past 12 months.  
Alcohol use: bivariate, the patient has/has not used alcohol to excess within the past 12 
months.  
Homelessness: bivariate, the patient, was/was not homeless at any time during the past 12 
months before the TB diagnosis. 
Occupation: multivariate, primary work within past year (correctional employee, 
healthcare worker, migrant/seasonal worker, student, disabled, homemaker.  
A resident of a correctional facility: bivariate, actively in correctional custody. 
Healthcare provider type: bivariate, local health department or private provider. 
Disease site: multivariate, site of disease (pulmonary, Extra pulmonary, both 
pulmonary/Extra pulmonary).  
Previous TB: bivariate, the patient has/has not had a prior diagnosis of TB. Sputum 
culture finding multivariate, indicates a (positive, negative, not done, unknown).  
Sputum smear finding multivariate, indicates a microscopic examination of sputum smear 
was (positive, negative, not done, unknown).  
Chest X-ray finding multivariate, indicates an initial chest radiograph showed (normal, 
abnormal, not taken, unknown).  
Status at diagnosis: bivariate, indicate patient was alive/dead at time of diagnosis.  
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DOT: multivariate, the patient received/did not receive directly observed therapy (self-
administered, observed, both, unknown).  
Multidrug-resistant: multivariate, yes/no patient is resistant to at least isoniazid and 
rifampin.  
Methodology used was advanced regression analysis to help identify discussed 
relationships and correlations to be tested that support or refute meaningful interpretations.  
Definitions 
Tuberculosis: laboratory criteria for diagnosis isolation of M. tuberculosis, MTB complex 
from a specimen by nucleic amplification or culture, or clinical case criteria with a positive skin 
test, two or more TB drugs, positive chest X-ray.  
AIDS: acquired immune deficiency syndrome: a severe disease of the immune system 
that is caused by infection with a virus (WHO, 2014b). 
 Coinfection: concurrent infection of a cell or organism with two organisms (CDC, 
2014a).  
Comorbidity: existing simultaneously with and usually independently of another medical 
condition (Merriam-Webster, 2015).  
Completion of therapy: to undergo medical treatment of an illness or disease while 
receiving all recommended drug regimens (CDC, 2014a).  
Demographics: statistical data relating to the population and groups within it (Oxford 
Dictionaries, 2015).  
Diagnostic Status: determination of a diagnostic test outcome or condition.  
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Drug Resistance: an organism does not respond to the standard initial drug regimen 
(CDC, 2014a).  
Extensively drug-resistant TB (XDR-TB): is a rare type of MDR TB that is resistant to 
isoniazid and rifampin, plus any fluoroquinolones and at least one of three injectable second-line 
drugs (CDC, 2014a). 
Foreign-born: a person whose country of origin is outside the United State (CDC, 2014a).  
Homelessness: a condition of people without a regular dwelling, often unable to acquire 
and maintain consistent, safe, secure and adequate housing (WHO, 2014b).  
Human immunodeficiency virus: "HIV" the virus that causes HIV infection in humans 
(WHO, 2014b).  
Intravenous: situated, performed, or occurring within or entering by way of a vein; also:  
used in or using intravenous procedures (Merriam-Webster, 2015). 
Kaposi's sarcoma: a rare form of a relatively benign cancer that tended to occur in older 
people (CDC, 2014b). 
 Latent tuberculosis infection: a person diagnosed with TB infection with a laboratory 
diagnostic evaluation (CDC, 2014a).  
MTB: Mycobacterium tuberculosis the organism that causes TB disease and Latent TB 
Infection LTBI (CDC, 2013).  
Multidrug-resistant (MDR) TB: results from an organism that is resistant to at least 
isoniazid and rifampin, the two most potent TB drugs (CDC, 2014a).  




             
Previous History of Treatment: determination of TB treatment initiation from a clinical or 
diagnostic determination of TB disease (CDC, 201a).  
Program Collaboration & Integration: a systematic consolidation of programmatic 
resources and services to improve health outcomes (CDC, 2014a). 
Quality of Life: individuals' perceptions of their position in life in the context of the 
culture and value systems in which they live and about their goals, expectations, standards, and 
concerns (WHO, 2002).  
Report of Verified Cases of Tuberculosis: an annual report published by the Centers for 
Disease Control & Prevention that describes TB in the United States.  
Substance Abuse: overindulgence in or dependence on an addictive substance, especially 
alcohol or drugs (Miller & Hendrie, (2008).  
The Great Imitator: the term given to TB disease based on the ability to mimic symptoms 
of other diseases and illnesses based on radiographic images including types of pneumonia, 
cancers, sarcoidosis, and HIV/AIDS (CDC, 2014a).  
Unemployed: a person without a paid job but available to work (Merriam-Webster, 
2015). 
Assumptions 
The research performed in this project consisted of secondary data from the National 
Tuberculosis Surveillance System (NTSS), and I have assumed that systematic data collection 
has occurred between 2009 and 2014 and definitions related to surveillance and demographic 
data have not significantly changed in meaning and scope. The guidance reflects that all 61 CDC 
reporting areas are required to report data regularly to NTSS, but individual platforms, 
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messaging, and systematic limitations may reflect in missing data points and variables. All 
reported TB cases and HIV positive status was validated by laboratory confirmation or will 
receive a "clinical" diagnosis based on physician findings.  
 Provider diagnoses that do not meet either the clinical or laboratory case definition will 
be considered part of the verification and was not count based on evidence of treatment gaps or 
disease is verified again for cases lost to follow-up. Confidence in surveillance system data 
reporting is critical to the integrity of analysis. The study was conducted based on the premise 
that provider diagnosis "not a component of the case definition" is correctly noted in the RVCT 
to reflect the actual incidence of cases and surveillance activities genuinely indicate the exact 
number of reported cases. Validation and acceptance of case definition is a critical component of 
this study because the researcher must be sure that data indeed describes the disparities among 
the population.  
Scope and Delimitations 
HIV status was addressed in this study because, in previous editions of the RVCT 
document, HIV status was not a required element. In 2009, HIV infection was systematically 
collected and now provides a robust independent variable associated to coinfection for analysis 
in conjunction with the completion of therapy variable. Non-Hispanic Blacks are a subpopulation 
at high risk for TB and HIV requiring health interventions to improve their QOL and completion 
of therapy outcomes as described by CDC reports (CDC, 2014a). Several populations qualify as 
high risks such as children, persons with other medical conditions, homeless, diabetes, alcohol 
use or illegal drugs, or not treated correctly for TB in the past.  
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Each population warrants evaluation in a separate study, but I wanted to address CDC 
recommendation criteria for "persons at highest risk," program collaboration, and resource 
management regarding intervention strategies. Some demographic, clinical, and laboratory 
variables will be excluded to reduce many variables within the data set. This study evaluated 
eight years of aggregated data collection that will consist of more than 87 thousand records. 
Also, TB and HIV data went through rigorous regression analysis, including the 2009 data 
reported descriptive study.  
The most logical framework for this project was a longitudinal non-experiment design 
based on the extensive aggregated data set as described by (Creswell, 2009). The use of 
aggregated data will limit this study to quantitative methods and must rule out other designs 
based on the use of a finite data set leaving the researcher with no options regarding design such 
as qualitative approaches, or mixed methods. The SDOH model provided several core constructs 
that guided all analysis.  Other models such as Health Belief Model, Precede-Proceed, or Trans 
Theoretical model rely on an interpretation of data from subjects and will not suit the static 
nature of secondary data.  
Limitations 
This study may have inherent limits in the chosen methodology of secondary data 
analysis. Although the data set will be a representation of all reported cases in the U.S., the entire 
data set could reflect the detail of data entry practices of each jurisdiction. Binomial logistic 
regression analysis will only provide data that helps identify associations rather than cause and 
effect as seen with other designs such as experimental methods (Creswell, 2007). The NTSS data 
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set should capture the one significant HIV status variable and should not require a merger with 
the HIV/AIDS database but is limited to a bivariate analysis.  
The use of de-identified data prevents follow-up interviews and discussions from being 
performed with participants for clarifications.  The source of the data, sample size, and agency 
reputation are not in question, but vague data could produce less than robust associations. 
Misclassification of a race could occur. Thus, the researcher may need to be aware of selection 
bias of the data set regarding changes with variable definitions such as "confirmed case" which 
may have changed over time: for example, change in provider diagnosis 
Confounding is a significant concern because the completion of therapy dependent 
variable may have interactions with other factors; however, effects of an unmeasured, and or 
unknown variable. Large sample size and randomization may control the unknown variable 
(Creswell, 2009). One significant limitation of a non-experimental predictive design is the 
researcher may only rely on interpretations, observations, or interactions to conclude. The 
association for an increase in familywise error across statistical analysis was not controlled by 
Bonferroni Correction, thus this research is relatively preliminary, and replication is encouraged.    
To address study restrictions, associations, correlations, inferences, large sample size, and 
practical significance may help address some limitations.  Analysis were based on surveillance 
data that is aggregated from various reporting units around the United States. Thus, there may be 
some variability in data quality and completeness. Self-reporting of race may not be consistent 
and may vary depending on an individual’s perception about race and ethnicity. Centers for 
Disease Control and Prevention, (2007). Report of Verified Case of Tuberculosis 2009 may have 
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missing records prior to 2009, because reporting was voluntary. California did not report HIV 
status from (2008 – 2010). 
 
Significance of Study 
Research among Non-Hispanic Blacks to identify risk factors associated with completion 
of therapy and co-infection could provide a better understanding for all public health and private 
practice providers in the challenges that high-risk populations have in improving health 
outcomes for TB. Understanding characteristics associated with completion of therapy among 
race/ethnic groups may be valuable to define how each subpopulation relates to the others as 
well as their relative risk for completion of therapy. Aggregated data from (2009-2014) RVCT 
could provide the subject matter to fill in the gap identified by the lack of literature and allow 
this research to make a unique contribution to the literature and field of study.  
Both descriptive and advanced study could provide health care practitioners with data-
driven evidence that helps foster initiatives and interventions (CDC, 2014a). Interventions 
subsequently could be used to stop disease transmission and intervene against disease 
propagation and degradation of health. Correlations and associations may provide a foundation 
for understanding the variables that place non-Hispanic Blacks are at a higher risk for co-
infection and not completing treatment. This project may have the potential to impact and affect 
positive social change by providing public health practitioners variables that are significant to 
completion of therapy which improves the QOL and raises the standard of care for co-infected 
persons (CDC, 2014b).  
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Increasing the probability of cure through disease intervention may improve individual 
health outcomes as well as address population health determinants. Despite the decrease in death 
rates after receiving the antiretroviral therapy, they remain twice that of persons without HIV 
infection (Metcalf et al., 2013). Marks et al., (2011) reported HIV-infected TB patients have 4 to 
11 times OR of TB diagnosis at death and a 3 to 20 times the odds ratio of death during TB 
treatment as HIV-uninfected patients.   
Summary and Discussion 
This chapter discussed a longitudinal design that described the similarities between TB 
and HIV as outcomes that cause significant health problems for affected individuals while 
highlighting non-Hispanic Blacks and other race/ethnic groups. As a single condition, each has 
specific clinical management strategies and regimens that make overall care and the completion 
of therapy difficult for providers.  
In tandem, co-infection places additional clinical, physical, and operational challenges on 
the individual and provider that increases the negative impact on high-risk persons such as non-
Hispanic Blacks. Ethnic and racial disparities among blacks and other high-risk populations 
continue to be disproportionate in the United States (CDC, 2014b) and describing variables of 
association and correlations may help provide data to understand risk factors better.   
Chapter two will systematically review the literature on characteristics and peer-review 
research for co-morbidities related to high-risk persons such as foreign-born, Africans, Whites, 
Hispanics, U.S.-born, and missed opportunities in the national TB control program that could 
impact the standards of care for co-infected persons. This chapter will discuss literature search 
strategies, gaps in literature as well as sentinel studies that provide the foundation further 
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scientific evaluation. The section continues with highlights regarding the history of TB and 
HIV/AIDS and includes the significance of co-infection, associated problems, and epidemiology 
and treatment guidelines. The chapter concludes with a review of theoretical background and 





















             
Chapter 2: Literature Review 
Introduction 
This chapter used the SDOH framework to highlight peer-reviewed research for the high-
risk population with TB and HIV coinfection and challenges associated with surveillance, 
screening, testing, treatment, costs, and a variety of programmatic problems that impact the 
delivery of services. Also, this chapter outlined public health initiatives that address the 
problematic management strategies for comorbidities throughout the U.S. and describe several 
global initiatives that address the public health disparity of having two competing for health 
conditions and the impact of identifying resources to build capacity for short and long-term 
intervention. The purpose of this research was to use a quantitative framework outlined in SDOH 
essential components (policymaking, health services, individual behavior, and biology/genetics) 
conditions which people are born, live, work, age, and broader environmental factors that shape 
daily life (WHO, 2014a). Essential components of SDOH highlights advanced data analysis of 
the national RVCT data set. The ultimate intent of this study was to address the health inequity 
among race/ethnic groups to guide policies and political systems towards social change.  
The importance of program collaboration to battle reductions in funds was discussed to 
show the further effect on completion of therapy and provide a foundation that teaches an 
essential need for new research on all co-morbidities including TB and HIV.  The literature 
review was conducted to provide support for research questions discussed in chapter one. Even 
though TB rates have fallen in recent years in the United States, TB transmission among the 
high-risk population is still one of the highest concerns especially those living with HIV. People 
living with HIV are more likely than others to become sick with TB (CDC, 2014a).  
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High-risk populations such as non-Hispanic Blacks are one of the subgroups where new 
initiatives are needed to ensure testing, screening, evaluation, and treatment are available to 
improve completion of therapy outcomes resulting in the cure of TB (CDC, 2014a). Coinfection 
from TB and HIV requires complex treatment regimens and a cohesion of provider management 
to ensure adequate continuity of care to ensure completion of therapy for TB. Literature provides 
by CDC and WHO support guidance and promotes collaboration among health care delivery 
systems, but costs remain an essential barrier against co-morbidity initiatives (CDC, 2014a; 
WHO, 2014a). Considering complex treatment regimens and increased surveillance requirements 
for this population, decreases in funding across both TB and HIV programs makes management 
activities difficult for public health and private practice practitioners to provide services that 
reduce incidence among persons with co-infection (WHO, 2014c).  
Literature Search Strategy 
The literature review was conducted using several forms of scholarly research databases. 
Walden University Library resources provide a significant portion of obtaining peer-reviewed 
literature. The EBSCO database offered several of the disease-specific searches for TB and HIV. 
The links from EBSCO databases led directly to CINAHL, MEDLINE, and Health Source 
search engines for the keywords:  
1. TB and HIV co-infection; 
2. Non-Hispanic Blacks health disparities; 
3. Comorbidities HIV/TB; 
4. HIV disparities; 
5. Completion of Therapy HIV/TB; 
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6. HIV among non-Hispanic Blacks; 
7. TB among non-Hispanic Blacks; 
8. High-risk populations; 
9. Comorbidities, and 
10. TB/HIV RVCT guidelines. 
Many resources come from CDC.gov, ProQuest, Mayo Clinic.org, and the US 
Department of Health and Human Services. The scope of literature consists of retrospective 
research performed in the past five years. Most studies were longitudinal in design evaluating 
aggregated databases identifying epidemiological trends. Longitudinal studies covered a 10-year 
span and provided a retrospective linkage between TB cases with HIV.  
Theoretical Foundation 
Research evidence suggests that public health promotions are more effective when they 
are driven by behavioral and social science theories more so than those advertisements that lace a 
theoretical base (Glanz & Bishop, 2010). Glanz and Bishop stated that science theory challenges 
are a result of contemporary perspectives of multiple levels of SDOH and behavior. The health 
belief model (HBM), trans-theoretical model (TTM), and social cognitive theory (SCT) all 
contribute and help researchers translate raw theory into a framework used in health behavioral 
intervention research.  
The HBM was developed in the 1950s by a public health service psychologist to explain 
the failure of individuals to get involved with their health care to prevent and detect disease 
(Glanz et al., 2008; Hochbaum 1958). The HBM came into existence during Hochbaum’s US 
Public Health Service study which examined factors associated with TB screening programs. 
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This investigation was a part of a newly initiated behavior science section outlining constructs of 
the HBM model:  
1. Perceived Susceptibility – an individual’s belief about getting a disease or condition;  
2. Perceived Severity – the seriousness of contracting an illness and associated outcomes 
such as death, disability, pain, and social consequences;  
3. Perceived Benefits – change of behavior based on the individual’s perception that 
benefits of actions will reduce the threat of disease; 
4. Perceived Barriers – potential adverse effects of the preventive measure may affect the 
individual health action;  
5. Cues of Action – preparedness, strategies; and 
6. Self-efficacy – internal ability to act (Glanz et al., 2008). 
The SCT involves reciprocal determinism, an interaction between people and their 
environment (Glanz et al.,). Bandura (1977) developed the latest edition of the theory previous 
called social learning theory. The SCT suggest that the environmental manipulation by an 
individual may be altered to suit the purpose of that individual, which emphasizes the human 
ability for collective action constructs of SCT;  
1. Reciprocal Determinism – environmental factors that influence individuals; 
2. Outcome Expectations – beliefs regarding values of consequences of choices; 
3. Self-Efficacy – beliefs that an individual can perform behaviors; 
4. Collective Efficacy – beliefs that specific actions bring results; 
5. Observational Learning – learned behaviors with exposure to media or interpersonal 
displays through peer modeling; 
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6. Incentive Motivation – positive responses or rewards for behavior modification;  
7. Facilitation – providing resources that make change possible;  
8. Self-Regulation – controlling actions through corrective strategies and social support; 
and  
9. Moral Disengagement – ways of thinking that justify suffering as acceptable and part of 
an individual’s moral standards (Glanz et al., 2008). 
The TTM involves several stages of change integrated with process principles of reform 
that cross many intervention theories which result in the term “transtheoretical” model.  
Prochaska and DiClemente (1982) conducted a study on smoking cessation where they 
developed the foundation behavior studies among smokers. Researchers concluded that behavior 
change played out in stages. Since the publication of this study, the model has grown into a tool 
to develop health interventions for persons with health and mental disorders, depression, eating 
disorders, obesity, and many other health conditions that require disease-specific interventions 
(Glanz et al., 2008). The TTM has undergone many refinements since first introduced in 1982 
and has developed into the latest configuration. Six States of Behavior change:  
1. Pre-contemplation – no intention to change behavior within six months; 
2. Contemplation – plans to act within the next six months; 
3. Preparation – intends to act in the next 30 days, has taken some steps towards starting; 
4. Action – changed behavior for less than six months; 
5. Maintenance – changed behavior for more than six months; and 
6. Termination – no relapse or temptation 100 percent confidence (Glanz et al., 2008). 
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Ten Model constructs to determine processes of change consists of covert and overt activities 
that individuals use to get through the stated stages. The following ten operations have the most 
research support in the psychological community:  
1. Consciousness-raising – increased awareness of an outcome; 
2. Dramatic relief – increased emotional experiences; 
3. Self-reevaluation – cognitive and affective assessments; 
4. Environmental reevaluation – assessments of behavior on the environment; 
5. Self-liberation – belief that one can change; 
6. Social liberation – increase in social opportunities; 
7. Counterconditioning – substituting good behavior for problem behavior; 
8. Stimulus control – remove unhealthy habits adds good habits; 
9. Contingency management – consequences for taking steps in positive or negative 
directions; and 
10. Helping relationships – relationships that support healthy behavior change (Glanz et al., 
2008).  
In understanding models of health behavior, practitioners concentrate on the individual as 
an essential unit of research and practice. The individual is not the only element of an 
intervention but indeed is a critical component. Other practitioners are involved in this process 
such as groups, organizations, worksites, and communities contribute which are composed of 
individuals (Glanz et al., 2008). The HBM has been used in countless areas of health care and 
public health including studies for breast cancer, smoking cessation, risky sexual behaviors, and 
treatment completion studies. The core use of the HBM is in the adaptability it has for 
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incorporation into other models and frameworks. Vazini and Barati, (2014) published a study 
that used constructs of the HBM as a behavioral-analytic framework to predict behaviors related 
to diabetes.  
Some challenges of using the HBM alone for future research is limited because it does 
not consider the emotional component of behavior (Glanz et al., 2008). Glanz et al. (2008) 
suggest that cues of action are a component missing from research and influences behavior when 
perceived threats and benefits are high, and perceived barriers are low. In contrast, the SCT 
focuses on the interaction of people and their environment as opposed to the focus of individuals 
as seen with HBM. The SCT constructs concentrate on people’s ability to alter their environment 
to meet their individual needs showing the capacity to facilitate collective action. In contrast, the 
HBM highlights personal perceptions, modifying factors, and the likelihood of activity in the 
conceptual model which offers a framework that has been popular among researchers (Glanz et 
al., 2008).  
One of the most significant limitations of SCT is that the constructs are broad and 
confusing to focus on an intervention (Bandura, 1986; Glanz et al., 2008). The TTM has 
limitations as well but offers multiple constructs which help researchers develop frameworks for 
public health interventions. The theoretical foundation of HBM, SCT, and TTM are grounded in 
research and support determine behavior change (Glanz et al., 2008) This academic foundation 
collectively help researchers develop health equity promotions grounded in theory. Individual 
theories such as HBM, SCT, and TTM drive initiatives framed under SDOH that focuses core 
theoretical constructs on helping practitioners understand relationships between people and their 
environment (WHO, 2014c). 
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  Equitable distribution of population health ensures reduced health care disparities among 
citizens. Improving overall population health outcomes have become one of the highest priorities 
among policymakers, health professionals, and community-based organizations both 
internationally and domestic (Sadana & Harper, 2011; WHO, 2014c). The WHO Commission on 
the SDOH reported all health-damaging experiences are not natural occurrences, instead of many 
are structural determinants generated from poor social policies, programs, unfair practices, and 
politics which promotes social, economic, and health discriminations. Each determinant can link 
to a condition associated where people live, grow, work, and age (WHO, 2014c). The WHO 
Commission set an agenda to address three areas in reducing health inequities that are a part of 
the 2020 initiatives to improve health outcomes:  
1. Improve daily living conditions; 
2. Address inequitable distribution of power, money, and resources; and 
3. Measure and evaluate the problem. 
Conceptual Foundation 
The conceptual foundation of SDOH is evidence-based which focuses on relationships 
between determinants and outcomes (Sadana & Harper, 2011). The WHO and CDC support 
SDOH as their primary framework for health promotions and many studies reviewed in this 
research project using this context to describe how secondary data analysis help researchers to 
make inferences about health outcomes based on constructs of SDOH (CDC, 2014a; WHO, 
2014a;). Co-infection research, although limited, has provided several studies which researchers 
have used to describe SDOH in their discussion based on CDC and WHO recommendations. 
Chindelevitch et al., (2015), Rodwell, (2010), Pascopella, (2014), and Metcalfe, (2013) all used 
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fundamental constructs of SDOH in their research to influence policy within their communities 
and improve QOL among their high-risk populations.  
The four studies mentioned provide the bulk of coinfection research regarding TB and 
HIV, but Prussing et al., (2015) used SDOH through population-based surveillance to describe 
characteristics of viral hepatitis on health outcomes of persons with TB and HIV, which give 
some perspective on resource collaborations required for managing co-morbidities. The Prussing 
study showed how the researcher is trying to change policy and the way health services are 
delivered to make sure those at highest risk are reached. 
 
Figure 1. Social determinants of health. Note: Adapted from Healthypeople.gov. 
Literature Review 
In recent years, TB/HIV coinfection has become one of CDC’s most discussed infectious 















             
creative and collaborative interventions to help reduce rates among high-risk populations (CDC, 
2014a).  Pascopella et al. (2014) conducted one of the most comprehensive research studies to 
assess opportunities for TB diagnosis and prevention among persons living with HIV. In this 
cross-sectional study, they evaluated policy and practices at four large Ryan White program-
funded HIV clinics.  
Pascopella et al. (2014) is a seminal study that addresses opportunities for TB diagnosis 
and prevention among persons living with HIV across more that on clinic or site. This study was 
one of the first to implement the program collaboration across a broad platform which provides a 
comprehensive analysis of coinfection in the United States. A review of literature performed by 
Briggs, Emerson, Modi, Taylor and Date (2015) provided a glimpse of co-infection research 
which outlined only Isoniazid therapy as a precaution among people living with HIV/AIDS.  The 
researchers state that implementation of such a program has been “slow” in many high burden 
programs. Methods used were an advanced logistic regression with odds ratios. Researchers 
reviewed medical records from a 600-person random sample of HIV-infected patients who had 
experienced at least one visit in 2009 from four clinics in New York and Los Angeles 
metropolitan areas (Briggs et al., 2015). Researchers described testing and treatment for LTBI 
during the years of 2008-2010 and estimated odds ratios for obtaining TB services. Results 
indicated that 79 percent received testing and 21 percent did not (Briggs et al., 2015). Odds ratios 
describe test levels and degree of treatment after testing positive for TB.  
Odds ratios suggested that among the four chosen clinics, routine testing of patients with 
LTBI did not always document treatment in a population at high risk for developing TB. Odds 
ratios for non-Hispanic ethnicities OR = 4.9 in comparison to non-Black race at OR = 1.7 
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(Briggs et al., 2015). Non-Hispanics were less likely to receive treatment for LTBI and Blacks 
were less likely to receive a chest x-ray to rule out TB. This study is significant to understanding 
co-infection through a systematic approach which serves as a positive outcome for researchers to 
build individual disease-specific designs.  
The Pascopella et al., (2014) research is a sentinel study that provides the basis for a 
further investigation under the model of non-Hispanic Black characteristics for completion of 
therapy. Abraham, Winston, Magee and Miramontes (2012) not only highlighted the importance 
of managing co-infection in describing clinic deficiencies; they also identified the disparity 
among non-Hispanic persons compared to non-Blacks. Treatment is recommended to ensure that 
LTBI does not progress to active TB. (Alami et al., 2014; WHO, 2014a). Research determined 
that in big city clinics, HIV programs often test for TB, but follow-up for TB treatment is 
deficient in many circumstances requiring policy changes and practices (Pascopella et al., 2014).  
The strength of this study lies in the clinic-based patient-level data where the use of 
specific variables is beneficial versus aggregated data which only allows the researcher collect 
data for other reasons (Creswell, 2009). This research shows that clinic-level data can be used to 
manage co-infection when the use of a surveillance system is in play. My project benefits from 
this programmatic review by using surveillance systems as a critical component to building an 
intervention design. Rodwell et al., (2010) sought to understand co-infection trends in San Diego 
County, California comma to identify sociodemographic risk factors associations among persons 
with TB and HIV co-infection.  
Researchers described the importance that HIV has on TB disease and LTBI reactivation 
in the rate of disease progression. Rodwell et al., (2010) stated that TB disease also accelerates 
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HIV disease progression and reduces the effectiveness of HIV treatment. Researchers say that 
co-infection is a worldwide crisis and directly affects TB elimination for domestic and 
international partners. The methods used by researchers were an advanced analysis of the 
California TB Surveillance System data from 1993-2007 of 5,172 verified TB cases.  
Cases were grouped by HIV status: positive, negative, or unknown. Of the stated 
instances 8.8 percent were infected with HIV (Rodwell et al., 2010). Poisson regression analysis 
was used to identify trends and associations between TB and HIV using social and demographic 
variables for analysis. Results of the study suggest that co-infection among Hispanics was 
significantly higher than those of non-Hispanic Whites and Blacks in San Diego, concluding that 
the burden of co-infection has shifted from Blacks to Hispanics in the past ten years (Rodwell et 
al., 2010).  
Researchers approach the co-infection problem by identifying their high-risk population, 
which in fact had moved to implement interventions recommended by CDC (Rodwell et al., 
2010). Researchers determined that their response should include a binational approach because 
over 80 percent of co-infection cases are Hispanic. Mexico lacks current resources and policy 
guidelines for contact tracing; collaboration with resources would be an excellent opportunity to 
strengthen their TB control program (Rodwell et al. 2010). 
The strength of this study lies in the baseline data gathering of a co-infected case to 
identify associations. The weakness in their approach is retrospective in nature, whereas some 
key statistics cannot be measured (Creswell, 2009). The variables selected for use were 
appropriate under the rationale of their design to identify associations among variables. In 
response to the global concern to develop initiatives that address co-infection outside the United 
43 
 
             
States, McDonald, Smith-Palmer, Wallace, and Blatchford (2015) conducted a study in Scotland 
to access HIV infection as a contributing factor for TB as compared to other industrialized 
countries.  
Researchers performed a longitudinal retrospective study in Scotland among co-infected 
persons between 2001-2010 to investigate risk factors for their high-risk population of persons 
usually born outside the country, Black or African ethnicity, and refugees, with extra-thoracic 
lymph node involvement or disseminated TB disease. Researchers extracted 4,097 records from 
the TB surveillance system database, and 6,790 HIV cases were anonymously linked together 
(McDonald et al., 2015). Statistical analysis with SPSS for logistic regression was performed to 
identify associations between co-infection cases and variables for ethnicity and refugee status.  
The result described a low incidence of co-infection in Scotland, less than three percent 
having HIV, which was lower than expected. Most co-infected persons were foreign-born with 
an advanced pulmonary disease which is associated with high-risk transmission (McDonald et 
al., 2015). The strength of this methodology is that researcher recognized the link between HIV 
and TB as high risk and sought to investigate how it affected their community.  
The results were not statistically significant, but the fact that those with co-infection were 
worse resulting in more advanced stages of disease is a confirmation that collaboration among 
programs is a must. The most significant weakness of the study is the bias regarding the HIV 
registry. Not all persons with TB are required to undergo an HIV test, which results in the 
potential of undiagnosed persons with HIV being missed and not included in the study sample. 
McDonald et al., (2015) used advanced logistic regression with predictor variables for ethnicity 
and refugee status which are strong indications for this data set and rationale for analysis.  
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Metcalfe et al., (2013) is one of the few published studies in the United States that 
attempts to understand the epidemiology of TB. Researchers in California cross-matched TB 
cases from a centralized state database with cases in the state HIV/AIDS registry for the period 
of 1993-2008. According to the researchers, effective management of co-infection requires an 
understanding of disease epidemiology to improve survival. The study population of 57,527 TB 
cases was analyzed, 3,904 cases had no HIV status. Although TB rates in California had declined 
during 1993-2008, rates among Hispanics and non-Hispanic Blacks were the highest (Metcalfe et 
al., 2013).  
The method used in this study was primarily multivariate associations with a DV of 
“death” among TB/HIV patients using relative risk (RR) estimates and co-variates for a time 
period, age sex, race, ethnicity, foreign-born, and CD4+ count (Metcalf et al., 2013). Researchers 
concluded that foreign-born persons were at highest risk of death. Hispanics accounted for the 
highest number of co-infection cases at 57 percent while the instances involving Blacks and 
Whites declined during the period (Metcalf et al., 2013). The strength of the study is the detailed 
regression analysis to generate RR estimates for all categories. The most significant limitation of 
this study was that not all TB cases were a match with HIV status.  
Thus, those unmatched reports were HIV-negative. Providers that did not adhere to the 
CDC guidance for AIDS which may reflect in statements and not be inclusive to this sample. 
The rationale the researchers used in this study is very much appropriate for identifying 
associations among co-infected persons in California. Abraham et al., (2013) performed a cross-
sectional study using the NTSS data set from 2000-2009 to determine association for the high-
risk African populations living in the United States.  
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This study used advanced logistic regression analysis to describe the characteristics of TB 
compared to other foreign-born persons residing in the United States. Although this study did not 
necessarily take the approach of co-infection, researchers determined that Africans are more 
likely to be HIV-positive and have advanced TB disease in other population (Abraham et al., 
2013). The methods used in this study were bivariate analysis calculating odds ratios for HIV 
status, age, race, ethnicity, substance abuse, homelessness, site of disease, years in the U.S., and 
gender.  
Researchers addressed many of the independent variables outlined in my research to 
identify association but did not account for the dependent variable of completion of therapy 
(Abraham et al., 2013). HIV-status was the dependent variable of choice but has similar 
characteristics in scope with non-Hispanic Blacks regarding determining relationships of HIV-
status to include co-infection or not as a critical factory to the outcome for Africans. Also, 
researchers concluded that their research is the first to elicit characteristics of TB patients 
diagnosed in the US but born in Africa, which has a public health burden of syndemic TB and 
HIV cases and are three times higher than others foreign-born persons (Abraham et al., 2013).  
The strength of this study was the importance researcher made to address at-risk 
populations in the US and highlighting HIV as a co-morbidity by suggesting that clinicians who 
treat TB need to understand “risk profiles” of their patient populations and develop an approach 
accordingly (Abraham et al., 2013).The  most critical weaknesses observed in this research was 
the omission of data from California and Vermont for the study period. Other California patients 
had missing HIV data which added a level of collection bias to the study.  
46 
 
             
Nonetheless, this literature is essential to this design because it begins to touch the 
surface of co-infection indirectly with HIV-status and considers a national shift in policy as a 
strategy for disease intervention. Briggs et al., (2015) published a meaningful review of literature 
that took a systematic look at the use of isoniazid as a preventive therapy (IPT) among people 
living with HIV/AIDS. The methodology used was a review of 2,228 articles of Persons Living 
with HIV “PLHIV” eligibility for use in the study were those published between 1995 and 2013 
that included variables mortality, morbidity, and retention of care IPT in low and middle-income 
countries.  
After exhaustive abstract reviews, 2,132 articles did meet researcher inclusion criteria. At 
the end of a full theoretical investigation of the remaining 96 sections, only 55 meet the analysis 
criteria. Thirty-eight of those reports provided mortality data used in the study (Briggs et al., 
2015). A total of eight Retrospective Control Trials (RCTs), nine cohort studies, two case-control 
studies, and three systematic reviews made the final selection for persons receiving IPT.  
Researchers stated their purpose was to understand variables associated HIV-associated 
deaths: TB is the leading cause of death among persons with HIV/AIDS (CDC, 2014a; WHO, 
2014a). Isoniazid preventive therapy has the potential capability of decreasing TB related deaths, 
but programs around the world have been slow to implement this strategy in both TB and HIV 
endemic settings (Briggs et al., 2015). The rationale described by the researchers for conducting 
an exhaustive literature review for suggests that prevention is one of the most critical activities to 
reduce the burden of HIV mortality for PLHIV. Briggs et al., (2015) recommend the best 
strategy for preventing TB disease is to include antiretroviral therapy (ART) as an early 
treatment regimen to reduce incidence rates.  
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Despite the success of noted by several studies in this review, researchers agreed that 
risks are significantly higher for PLHIV that those without HIV, suggesting that IPT strategies 
should be implemented to prevent TB as described by the WHO since 1998. The conclusion of 
the review supports CDC and WHO recommendations for IPT to PLHIV to reduce morbidity. 
There is a significant benefit to persons who test positive for TB, treatment should be offered to 
all PLHIV regardless of presumptive TB (Briggs et al., 2015). Most articles reviewed that were 
qualified by this study focused on the dependent variable of TB completion of therapy regimen 
for both TB disease and LTBI. HIV-status was usually the independent variable as a constant 
with covariates for age, gender, housing status, homelessness, unemployment, and previous 
treatment under the logistic regression design to determine odds ratios and correlations for the 
co-infection’s population at risk.  
The main problem with the review is consistency regarding limitation in data collection 
and unpublished data. Efficacy of treatment regimens, adherence to treatment, and adverse 
advents was not within the scope of this review. Briggs et al., (2015) was unable to address MDR 
TB in their study based on selection bias criteria for exclusion from the study, which further 
limited their ability to make conclusions for the variable. Briggs et al., (2015) could not address 
possible changes in case of definitions in their interpretations over time between 1995 and 2014.  
The interpretation of case definition could have included or excluded cases from the 
study depending on the year they were recorded in the surveillance system, thus placing selection 
bias into their research which provided evidence for further investigation. The significance of the 
joint studies discussed in this section is the individual components each offers in the 
understanding of what elements, resources, epidemiology, and specific variables are required to 
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manage persons with co-infection and which sub-populations are at highest risk for a disease. 
After components evaluation, the design of interventions strategies and case management 
activities can take place.  
Literature Review Related to Key Variables  
What remains to be studied? Research gaps in literature related IPT in PLHIV varies in 
many countries placing a social burden on capturing short course, long-life, or repeated 
treatment/therapy. Under this design, a systematic data collection system to collect variables 
required to access all co-infection variables and co-morbidities is necessary. Also, researchers 
must include variables for isoniazid drug resistance and MDR-TB. Briggs et al., (2015) 
suggested that pediatric articles used in their research was limited to only five articles and 
required further investigation to determine associations of medication. Finally, literature reviews 
show several short course treatment regimens which have different efficacies and adverse event 
profiles.  
Determining which settings are the most appropriate for each treatment regimen for 
resistance, duration and effectiveness require more investigations (Briggs et al., 2015). The 
rationale for the use of the SDOH depends on three key factors that help to ensure that the most 
productive in this investigation. The first and most compelling reason to use core theoretical 
constructs from HBM, SCT, and TTM as a foundation was the validity of the science through the 
long and prosperous history of empirical work that has yielded many of the accepted concepts in 
psychology. Progresses in health promotion and health behavior research has grown significantly 
with more precise metrics from the partnership among scientist and healthcare experts (Glanz et 
al., 2008).  
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The SDOH model is one of many strategies used to define and address the health care 
specific need to understand why particular populations are at higher risk for disease and adverse 
outcomes. The SDOH describe aspects of care, resources, support, covariates, dependent 
variables, and independent variables that may affect health outcomes such as completion of 
therapy. The correct tool must be chosen to correctly understand relationships between how 
populations groups experience both social and physical determinants (CDC, 2014a). The second 
reason is the recommendations of the WHO and CDC as guidance agencies that encourage 
public health practitioners to use a standardized approach and framework that is “place-based” 
where interventions are most effective (CDC, 2014a; WHO, 2014a).  
The third reason for the usage of SDOH is directly related to the parameters of secondary 
analysis of a disease-specific database. The large RVCT NTSS dataset captures variables linked 
to the framework of SDOH regarding demographics, disease status, outcomes, medical history, 
social, and economic factors that provide the data for analysis. The data technique of advanced 
regression allowed for the evaluation of associations for each research question. The first 
research question in this study describes the dependent variable that relates to completion of 
therapy of prescribed TB medications. The behavior outlined in this matter is what place-based 
determinants interact with a co-infection that corresponds to a person either taking or not taking 
their medication to completion.  
What behaviors - physical or social - associate with completion of therapy? The second 
research question asks; how is completion of therapy among race/ethnic groups affected by HIV? 
The third research question takes matter two a bit further concerning identifying specific 
demographic and clinical characteristics through analysis may jeopardize the relationship of TB, 
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completion of therapy, and HIV if control is present. Social Determinants of Health help to distill 
the variables necessary to confirm or deny any associations. The independent variables of HIV in 
research question two similarly corresponds to the same determinants outlined in SDOH and 
brings another variable into play that has several social components such as stigma that may 
have a significant association to completion of therapy.  
The last research question helps to refine the search for specific associations by 
accounting for covariates that may contribute to the social status of any person. Prussing et al., 
(2015) begin to ask what relationships are familiar with disease-specific conditions, they 
challenged the existing research by accounting for two medical conditions and determining how 
they collectively affect the health of an individual. Psychological theory alone does not provide 
the platform necessary for retrospective analysis and must be well-developed and applicable to 
the methods of data collection and the variables collected (Glanz et al., 2008).  
Summary and Conclusions 
Demonstrated in this literature review were several essential studies that captured the complex 
nature of TB and HIV completion of therapy among at-risk populations. The SDOH model 
provided the theoretical framework in most public health interventions outline through 
relationships, demographics, risk factors, and conditions that affect the quality of life of an 
individual. Despite the decline in TB rates and improvements in HIV therapy, coinfection remains 
a health disparity that requires specialized strategies and interventions to reach populations such 
as Non-Hispanic Blacks and other high-risk populations in the United States.  
Most research regarding co-infection exists outside the United States in Sub-Saharan 
Africa and other European countries. Surveillance is the dominant theme of the studies reviewed. 
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Outside the United States, surveillance activities are less advanced but examine large sample sizes 
and different interventions which are more technical regarding high volume study numbers and 
populations. Research is limited both outsides and inside the United States that targets smaller at-
risk people seen in local and state jurisdictions. Smaller communities require specialized resources 
and activities to address demographic trends. The overall message of U.S.-based studies is the 
importance to reach high-risk populations, but resources and funding limit the effectiveness of an 
individual health department or state program.  
Agencies such as the CDC and WHO provide guidance that describes the problem of 
reaching high-risk communities, including non-Hispanic Blacks, but they offer no definitive 
solutions regarding cost sharing activities or resources. What we know about co-infection is the 
importance of treatment, the importance of case management, and most important the completion 
of therapy. What we known about coinfection of at-risk populations including non-Hispanic 
Blacks is what variable or variables may contribute to improving completion of therapy.  
This study may help bridge the gap in the peer-reviewed literature and provide a small 
piece of data to support researchers, practitioners, and public health professionals understand 
how RVCT data interacts with coinfection, completion of therapy, and other demographic 
covariates. Chapter 3 will describe the research design, population, recruitment, data collection 
procedures, instrumentation, materials, and statistical analysis used to determine associations 
among variables for completion of therapy, coinfection, demographic and clinical characteristics 





             
Chapter 3: Methodology 
Introduction 
The purpose of this study was to explore quantitative analysis of systematic data 
collected by the CDC in the national TB surveillance system using the RVCT (2009-2014) data 
to evaluate the differences between race/ethnic groups in predictors of completion of treatment 
completion of therapy among U.S.-born patients with TB and HIV co-infection (Alami et al., 
2014). This chapter includes a detailed description of the longitudinal research design and 
rationale, discussion of sample population and recruitment, the measure of variables, data 
analysis, instrumentation and materials, statistical analysis, procedures, ethical procedures, and 
summary.  
Variables proposed for examination include age, gender, HIV status, homelessness, 
injection drug use, alcohol use, and occupation, a resident of a correctional facility, type of 
healthcare provider, multidrug-resistance, and noninjecting drug use. Other essential variables 
proposed for examination include disease site, previous TB, sputum culture finding, sputum 
smear finding, chest x-ray finding, and status at diagnosis, directly observed therapy, and 
completion of therapy.  
Research Design and Rationale 
Completion of therapy will serve as the dependent variable with a dichotomous 
designation of yes or no. The case definition per the RVCT outlined a clinical description, 
laboratory criteria for diagnosis, and case classification of confirmed that meets the clinical case 
definition or is laboratory confirmed (RVCT, 2009). Although the requirements were 
complicated, the case definition ensured that consistency of reporting was systematic throughout 
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all 62 reporting project areas in the United States. Independent variables evaluated in the study 
were numerous demographic and clinical characteristics of U.S.-born Non-Hispanic races with 
HIV and TB compared with U.S.-born non-Hispanic Whites.  
Independent variables include age, gender, HIV status, homelessness, injection drug use, 
alcohol use, occupation, a resident of a correctional facility, health care provider type, multidrug-
resistance, noninjecting drug use. As well as disease site, previous TB, sputum culture finding, 
sputum smear finding, chest x-ray finding, status at diagnosis, directly observed therapy, and 
completion of therapy (all independent variables discussed record as dichotomous and 
categorical entries). An evaluation of the moderating variable for HIV status as a dichotomous 
input after controlling for all noted independent variables. A longitudinal quantitative research 
design was used to analyze secondary of data for persons diagnosed with TB and HIV reported 
in the RVCT database.  
The conceptual framework used in this model was taken from the CDC recommendations 
outlined in SDOH to identify intervention themes which may help practitioners identify agent, 
host, and environment for disease interaction intervention, and disruption of transmission (CDC, 
2014a). The longitudinal research design could provide a flexible time dimension in capturing 
co-infection data from the CDC RVCT tool.  This longitudinal model is not resource dependent 
regarding operational costs, personnel costs, and other costs such as incentives and enablers as 
associated with cohort designs (Creswell, 2009).    
Although the design is straightforward in data collection methods and posed fewer 
resource constraints, gaining access to the data set was time-consuming and required several 
months for the CDC Analytic Steering Committee to approve my proposed analytic plan. Despite 
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the lengthy approval process, the timeline was consistent with the design choice and offers 
another component of project validation from a reputable agency. Literature reviews supported 
the use of cross-sectional designs in public health interventions mainly concerning TB therapy. 
Mitruka, Winston, and Navin (2012) used a cross-sectional methodology to outline predictors of 
failure in timely tuberculosis treatment completion in the United States.  
Researchers used a Poisson regression analysis to assess predictors of failure in 
completion of therapy. Metcalfe et al., (2013) use a cross-sectional design and multivariate 
regression analysis to evaluate the potential impact of enhancing HIV treatment and tuberculosis 
control programs on the burden of tuberculosis. The longitudinal design choice was essential in 
measuring differences between or from a variety of people drawing inferences from existing 
differences between people subjects or phenomena (USC, 2016).  
Methodology 
The target population proposed in this study consisted of all U.S.-born “counted” TB 
cases with HIV infection reported by local, state, and private providers in the United States that 
meet the clinical case definition and laboratory criteria for diagnosis, and case classification for 
confirmed entered in the National Tuberculosis Surveillance System (RVCT SSM, 2009). In 
2014 the national TB case count was 9,421 reported to CDC for 50 states and the District of 
Columbia, 6 percent of reported TB cases were HIV positive (n = 492). The target sample 
population were TB patients reported to CDC during (2009 and 2014) coinfected with HIV and 
eligible to complete treatment (that is: not dead at diagnosis) was (n = 4,360) (CDC, 2013).  
Among this population, age categories were broken down into 0-14 years, 15-44 years, > 
44 years, and unknown. The sampling strategy deployed in this study was criterion-based for 
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subpopulations of U.S.-born Non-Hispanic races with HIV compared to U.S.-born Non-Hispanic 
whites. Criterion-based sampling involves selecting specific cases that meet a predetermined 
criterion of importance set by the researcher (Creswell, 2007).  
The overarching reason for selecting this method was to tease out all HIV negative cases 
and isolate CDC outlines those persons at highest risk of death and degradation of health based 
on immunocompromised guidance. Guidance state that without treatment, opportunistic 
infections such as HIV and TB can work together to shorten lifespans (CDC, 2014a). Persons 
that were the U.S.-born with co-infection will provide the platform for the application of 
regression analysis 
Procedures 
A proposal for an analytic plan was submitted to the Division of Tuberculosis 
Elimination at CDC Atlanta on 2 February 2016 that was not approved base on an unclear 
analysis plan. I sent a revised analysis plan on 18 April 2016 which was agreed on 30 April 2016 
to work with the NTSS 2009-2014 RVCT dataset with guidance from the division data steward 
and provide him with the completion of therapy dependent variable and other independent 
variables approved in the analytic plan. The data steward prepared and exported an Excel file 
conversion from the CDC standard SAS output that was imported and converted into an SPSS 21 
Statistical Analytical Software output and secured by the data steward on the CDC secure server 
for future analysis after IRB approval for this project.    
A study population sample comes from the CDC surveillance section which includes 
78,543 total cases reported between 2009 and 2014. A cross-tabulation analysis for U.S.-born, 
HIV positive, non-Hispanic cases was performed in SPSS to yield a sub-population data set of 
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2,192 cases to validate that the power requirement for a robust analytic plan. The recommend 
power for binomial logistic regression is a minimum of 15 cases per variable (15 x 81) 
(n=1,215). If the data is skewed, the recommendation is 20 cases per variable or (n=1,620) 
(Field, 2009). The dataset consists of clinical and laboratory criteria described in the 2009 RVCT 
guidance document for confirmed cases.  The variable for completion of therapy was 
recommended for recording by the data steward into a dichotomous format to account for 
reasons therapy was extended and accommodate treatment regimens that take longer than 12 
months per data dictionary definition (RVCT, 2009).  
                                                 Recruitment 
The sampling frame for inclusion criteria will include all U.S.-born non-Hispanic racial 
groups to include U.S.-born Hispanics as a separate race. The CDC collects case reports from the 
50 states and the District of Columbia (DC). All received case reports go through a passive 
surveillance process from health departments, and healthcare providers before submission go 
forward. Health departments conducted active surveillance activities through contact and 
interaction with healthcare facilities or individual providers to stimulate disease reporting (Alami 
et al., 2014). All cases were required to meet the case definition for clinic and laboratory 
confirmation with a recorded HIV positive status. One of the most crucial inclusion variables 
included in this study was age.  
The age variable was recorded as categorical data to include children, adolescents, and 
senior adults. This criterion is critical to stratify data to ensure smaller errors in estimations 
(Creswell, 2009).  Patient and county-level data and variables are not necessary for this project 
and were exempt from this analysis to ensure confidentiality of individual. Laboratory 
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diagnostics for molecular assays were not used and limited to documentation of positive smear 
and sputum culture findings in compliance with the laboratory definitions of a case.  
                                  Categorical Racial/Ethnic Groups 
 Categorical, racial and ethnic groups were defined for all verified cases of TB and HIV in 
the analysis. Five categories were outlined for race and Hispanics as a race was also collected in 
the data and described in the data dictionary. Ethnic groups were collected as Hispanic and non-
Hispanic U.S.-born persons. 
•    All U.S.-born; 
•    U.S.-born Non-Hispanic Whites; 
•    U.S.-born Non-Hispanic Blacks; 
•    U.S.-born American Indian or Alaska native; 
•    U.S.-born Asian; 
•    U.S.-born Native Hawaiian and (other) Pacific Islander; and 
•    U.S.-born Hispanics. 
Exclusion criteria included all foreign-born cases with and without HIV status. Close 
attention was made not to add cases with HIV negative status to refine the sub-population in the 
most precise terms and reduce the size of the overall data set. Besides, internal data cleaning and 
quality assurance techniques by CDC surveillance will help to ensure that any one case was not 
counted twice within any consecutive 12-month period.  
However, case inclusion could occur in the data set if the individual was lost to 
supervision for more than 12 months status with TB disease verification for the second time. 
Genotype data was not relevant to this study because completion of therapy was not affected. In 
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contrast, drug resistance variables for MDR were significant because treatment times and 
regimens vary from drug-susceptible TB which may have associations with completion of 
therapy. These criteria completed the scrutiny of each RVCT data collection variable and series 
of responses pertinent to identify correlations all research questions related to co-infection and 
completion of therapy.   
                                                   Power Analysis 
The research design addressed correlations between variables of TB and HIV status and 
the completion of therapy within the sample population as the dependent variables. A power 
analysis using G*Power 3.1.9.2 statistical software will describe linear bivariate regression 
(Two-group) alpha = 0.05 and Power (1-B) probability set = 0.95 the total sample size requires 
198 participants. Under the difference between slopes, statistical test total sample size (n=1,215) 
determine whether the slopes were significantly different from each other. Longitudinal data 
provided 2,192 cases which satisfied requirements. The ability to reject the null hypothesis 
depends on alpha, sample size, and effect size (Field, 2010).  
Alpha is the probability of rejecting type I error, or the likelihood of rejecting the null 
hypothesis given the null hypothesis is true. Although alpha is considered arbitrary, it was 
chosen to challenge each hypothesis. Sample size, when increased, leads to more accurate 
estimates and the potential of finding what the researcher is looking for (Field, 2009). The choice 
to use a large sample size satisfied analysis requirement because the data set was robust which 
may lead to more accurate estimates. When the effect size is more significant, it can lead the 
researcher to understand the effect in the population (Field, 2009).  In this study alpha = 0.05 was 
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a moderate effect and chosen to identify statistical significance to help in the decision making of 
public health practitioners (Creswell, 2009).  
Data Access Procedure 
The requirements to obtain access and permission to analyze the NTSS 2009-2014 data 
set for the sample population involved the submission of a completed formal Analytic Plan. The 
analytic plan was prepared and submitted to the surveillance manager at the Centers for Disease 
Control and Prevention Division of Tuberculosis Elimination (DTBE) Analytic Review Panel for 
scientific integrity and feasibility. The plan outlined the principal investigator, author, project 
supervisor, methods of analysis, study population key variables; IT issues, analytic approaches, 
hypotheses, data table shells, study limitations, proposed times for start and finish analysis, 
proposed finish manuscript, statistical software used, and references. 
 In the process, the analytic review panel consisted of surveillance staff, epidemiologic 
experts, and medical officers to access the plan for merit and overall scientific relevance. The 
first proposal was submitted February 2016 and was denied based on insufficient methods and 
project description. On March 15th a revised plan was submitted and subsequently approved on 
20 April 2016 with comments from the review panel to move forward with completing training 
and system requirements. A data sharing agreement was required to receive final access 
including a timeline for publication of findings in a future edition of the CDC Morbidity and 
Mortality Weekly Report (MMWR).   
The entire approval process took several months, and data download of the 2009-2014 
data set was received on 15 May 2016. Agency stipulations require that all researchers must 
work on data at their work site. Making copies of the data set are not authorized at any time. A 
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Non-Research determination may be necessary to complete the agency process towards the end 
of the project period.  
Instrumentation and Operationalization of Constructs 
The CDC managed and sponsored RVCT database was fully implemented in 1983 as a 
national surveillance to collect information on new cases of active TB. All states in the U.S. 
report to this system through the RVCT form.  Downloads from several sources including 
CDC.gov and many local and state public health links provide regular access for surveillance. 
The appropriateness to this study is the capability of the surveillance system to be used by the 
CDC to identify trends, create reports, and develop priorities for a public health agency to 
implement disease interventions (RVCT, 2009).  
The basis for tool development depends on providing state and local TB control programs 
the ability to utilize reports and analysis from the RVCT to identify high-risk populations and 
identify outbreak trends within their jurisdictions. The CDC provides permission to use the 
surveillance tool for surveillance purposes, and confidentiality is following Section 308 (b) of the 
Public Health Service Act (42 U.S.C. 242m).   
The CDC implemented the National Tuberculosis Indicators Project (NTIP) with 
collaboration from the California Department of Health to validate the selected objectives and 
standardize the measurements related to the progress of meeting national objectives and goals of 
the data points collected within the RVCT.  A CDC team of experts TB Control staff from 
Colorado, New York State, Minnesota, and Tennessee worked to identify validity, reliability, 
and accuracy of each measure and designed a template. The data were submitted the National 
Tuberculosis Controllers Association (NTCA), the Advisory Council for the Elimination of 
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Tuberculosis (ACET), the TB education and Training Network (TBN). The Evaluation Working 
Group (EWG), and others to validate the indicators and guide the implementation of the RVCT 
(CDC, 2010).   
The RVCT instrument was previously used in 2005 by CDC for the entire US population 
of 14,093 active TB cases. The RVCT variables were revised and validate several times and 
made available to cooperative agreement recipients for TB control funding in 2008 for 
(completion of therapy, laboratory reporting, clinical reporting, genotyping, and case 
management variables) used in the current RVCT form (CDC, 2010).  
Operationalization Data Analysis Plan 
To investigate the relationship between variables regression analysis is the technique of 
choice. The SPSS Statistical Software package 25 provided the platform for all analysis. 
Software package addresses the entire statistical process from planning, data collection, analysis, 
and reporting (IDRE, 2016).  The analysis plan will begin with running the descriptive variable 
study for completion of therapy, HIV positive, TB case, and all demographic characteristics 
outlined in the data shell. Choosing the correct statistical test will consist of identifying the 
number of dependent variables completion of therapy =1 and matching the number of dependent 
variables described in the Institute for Digital Research and Education web page.  
Paring of variables through matching with measures and tests to produce a systematic 
procedure of running each test under the regression platform. Listed below is the logic of 
analysis progression to identify associations or correlations with each research question and 
hypothesis noted below:  
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1.  Descriptive Characteristics: frequencies, percentages, ages, cross-tabulations, mean, 
median mode, sum standard deviation, variance, range, minimum, maximum SE 
mean, skewness, and kurtosis, and ration statistics; 
2.  Binary Logistic Regression (BLR);  
3.  Characteristics of U.S.-born Non-Hispanic Races with HIV compared with U.S.-born 
Non-Hispanic whites: odds ratios, confidence interval, and probabilities; and 
4.   Bonferroni correction: multiple-comparison correction used when several dependent 
or independent statistical test are being performed on the same sample (Field, 2009).    
Data cleaning techniques began with the CDC RVCT requirements for reporting cases to 
the NTSS database with passive and active surveillance. Benefits of using RVCT data increases 
access to the completeness of data, improved data for program planning and policy development, 
sharing of accurate information with patient and health facilities (RVCT, 2009). The CDC 
promotes active surveillance for health departments and providers to contact and interact with 
healthcare partners to stimulate disease reporting and improve the accuracy of data. In response 
to quality assurance, the CDC provides self-study modules that help participants learn how to 
complete the RVCT form accurately.  
The RVCT expansion took place in 2009 which requires all agencies that report cases to 
counted cases of TB and suspected cases of TB or on a patient with LTBI (RVCT, 2009).  Upon 
receipt of the RVCT dataset data cleaning began with the Excel data file. The first step is to 
cross-tabulate completion of therapy with HIV and TB status. Once dataset reduction has taken 
place, all additional variable not identified in the analysis will require a systematic removal.  
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Running multiple computation methods will describe patterns of missing data values for random 
or non-random values.  
The next technique used was dummy coding of missing values for scale and nominal 
data. Running frequency analysis heled identify other variables and date accountability for each 
case. Data cleaning process: define error type, identify error instanced, correct errors, document 
error types, and modify data entry process to reduce future errors (Field, 2010). The rationale for 
inclusion of potential covariates and confounding variables helped minimize the number of 
variables chosen for the most productive model.  
Integration of all clinical and other relevant variables was considered to control 
confounding (Bursac, Gauss, Williams & Hosmer, 2008).  Development of a methodology to 
further address covariates and confounding began with the univariate analysis of each variable 
and based on the significance was selected for multivariate analysis. Fundamental parameters 
and result interpretation in this model were regression statistics including odds ratios, adjusted 
odds ratio, confidence interval, and p-values (McDonald et al., 2015). 
 
Research Question 1: What is the relationship between and individual’s ethnic/racial 
group membership among U.S.-born non-Hispanics with an HIVTB co-infection and the 
likelihood of completion of therapy?  
H01: There is no relationship between individual’s ethnic/racial group membership 




             
Ha1: There is a relationship between individual’s ethnic/racial group membership among 
U.S.-born non-Hispanics co-infected with HIV/TB and the likelihood of completion of therapy. 
Research Question 2: Is there a relationship/association for completing therapy among 
TB/HIV co-infected U.S.-born non-Hispanics with an HIV/TB co-infection moderated by 
completion of therapy eligibility?    
Ho1: There is a relationship/association for completing therapy among TB/HIV co-
infected U.S.-born non-Hispanics with an HIV/TB co-infection moderated by completion of 
therapy eligibility.   
Ha2: There is relationship/association for completing therapy among TB/HIV co-infected 
U.S.-born non-Hispanics with an HIV/TB co-infection moderated by completion of therapy 
eligibility. 
                                                 Threats to Validity 
Internal validity was an essential consideration in this study because it challenges the 
experimenter’s ability to conclude an outcome that is part of the actual result and no another 
factor (Creswell, 2009 p 162.) The primary focus under consideration for the design of this 
project was to minimize potential threats to internal validity through sound analytics and 
practices. Deciding which confounding variables to use may influence the dependent variable. 
Recoding imperfect variables such as completion of therapy helped avoid incomplete dependent 
variable analysis. Recoding all variables reduced the tendency for scores to regress toward the 
mean (Creswell, 2009).  
Instrumentation changes in the RVCT database were implemented in 2009 reduced 
changes in outcomes because the data set analyzed was after following differences between 2009 
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and 2014. By using only cases who were eligible to complete treatment within 12 months that 
were alive at the beginning of therapy addresses experimental mortality. External validity was 
also significant to the study design. Creswell, (2009) stated to minimize and avoid drawing 
incorrect inferences from a sample population towards other and past and future situations.  
This model required that the variable definition of the previous history of TB treatment is 
separated out as individual variables that do not interact with other independent variables.  To 
avoid multiple treatment interferences with patients who recorded prior TB treatment was 
counted based on each episode related to completion of therapy and case count definition of new 
cases of TB (RVCT, 2015).  
                                            Ethical Procedures 
Accessing data began by initiating a data usage agreement to gain access to the CDC 
RVCT 2009-2014 NTSS data set. I was required to submits a data analytic plan proposal to the 
Analytic Steering Committee (ASC) for research feasibility. My project was submitted January 
2016 which was not approved based on ASC recommendation to clarify variables. A revision 
was made to address each variable for analysis and resubmit for further evaluation. A revised 
analytic plan was submitted 20 April 2016 and was approved on 30 April 2016 with stipulations 
to have the project completed within one year.  In addition to developing a proposal, I was 
required to sign a data sharing agreement outlining use and scope of the data for my dissertation 
project.  
The data sharing agreement provided confidentiality information, institutional 
responsibilities, and policies each researcher must follow to ensure proper stewardship of these 
data. In the agreement, I was identified as the principal investigator. The Project Supervisor was 
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noted Dr. David Anderson dissertation Chair from Walden University. Bob Pratt, the CDC data 
manager, began the initiation the preparation of the data set. Upon determining the three key 
individuals in the data sharing agreement, Bob Pratt, Andrew Heetderks, and I were approved on 
17 April 2016.  
The last document I completed was a non-research determination agreement which 
outlined that no research would be performed on human subjects and that a CDC agency IRB 
would not be required.  The secondary use of research data has become more complicated with 
the development of new technologies, data sharing, storage, and database size (Tripathy, 2013). 
Confidentiality and security training were required and completed by attending an online training 
course.  
In the agreement, I would only receive access to view data and run analysis on agency 
grounds while attached to the secure intranet when Walden University IRB approved this project. 
A Walden University IRB approval number was granted on 12 May 2018 for this project 
identification number (03-12-18-0019022).  The NTSS data set is a de-identified aggregated 
surveillance system that houses state and county level demographic and clinical case 
management data. The only ethical concern using this level data will be to remove location date, 
that is, state and jurisdiction information substantially reducing the chance of anyone guessing a 
situation or individual within any jurisdiction.  
If the data has no identifying information or is entirely devoid of such information or is 
appropriately coded so that the researcher does not have access to the codes, then it does not 
require a full review by the ethical board (Tripathy, 2013). The CDC agency approval is spelled 
out in the data usage agreement. Walden University requires IRB approval for this project. There 
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were no additional concerns with access and use of data by the agency. Upon completion of the 
surveillance project, all files archives are to remain onsite with analysis codes for future analysis, 
plans, and follow-up. 
                                                      Summary 
The preceding sections described the longitudinal quantitative research design that was 
used to investigate association and correlations of demographic and clinical characteristics of 
U.S.-born non-Hispanic Races with HIV compared with all U.S.-born non-Hispanic races. 
Access to NTSS 2009-2014 RVCT was used to access relationships to the dependent variable for 
completion of therapy. The statistical approach of regression analysis provides the platform to 
understand what variables and associations were most appropriate for at-risk populations co-














             
Chapter 4: Results 
Introduction 
The purpose of this study was to identify persons with TB and HIV coinfections and 
compare the NTSS surveillance database variables associated with completion of therapy. 
Advanced regression techniques were used to describe correlations and associations of reported 
TB cases to predictor variables in the TB registry. In addition, the study focused on the 
subgroups of U.S.-born non-Hispanic Blacks to determine what variables are associated with a 
significant odds ratio for completing or not completing therapy across all variables and 
ethnic/racial groups.  
Chapter 4 outlines the systematic approach to data collection baseline descriptive 
statistics, variables collected, and justification for inclusion in the model. The chapter describes 
dependent and independent variables and their association to completion of therapy. Chapter 4 
also defines completion of therapy eligibility as described by CDC for all cases based on a 
complex algorithm that supports TB guidelines for completion of therapy within 12 months as 
the standard of care.    
Research Questions 
 The study was guided by the following two research questions that were focused on 
identifying variables associated with completion of therapy. 
Research Question 1: What is the relationship between and individual’s ethnic/racial 
group membership among U.S.-born non-Hispanics with an HIVTB co-infection and the 
likelihood of completion of therapy?  
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H01: There is no relationship between individual’s ethnic/racial group membership 
among U.S.-born non-Hispanics co-infected with HIV/TB and the likelihood of completion of 
therapy.  
Ha1: There is a relationship between individual’s ethnic/racial group membership among 
U.S.-born non-Hispanics co-infected with HIV/TB and the likelihood of completion of therapy. 
Research Question 2: Is there a relationship/association for completing therapy among 
TB/HIV co-infected U.S.-born non-Hispanics with an HIV/TB co-infection moderated by 
completion of therapy eligibility?    
Ho1: There is a relationship/association for completing therapy among TB/HIV co-
infected U.S.-born non-Hispanics with an HIV/TB co-infection moderated by completion of 
therapy eligibility.   
Ha2: There is relationship/association for completing therapy among TB/HIV co-infected 
U.S.-born non-Hispanics with an HIV/TB co-infection moderated by completion of therapy 
eligibility. 
Data Collection Sample Population 
The data for this project were collected and housed by the Centers for Disease Control & 
Prevention Division of Tuberculosis Elimination Surveillance, Epidemiology, and Outbreak 
Investigation Branch at the Atlanta Georgia headquarters. I used NTSS RVCT data from 2009 
thru 2014, note: the dependent variable completion of therapy (COT) and the reason therapy was 
stopped (STOPREAS) data may not be completed. Completion of therapy eligibility (COTELIG) 
was a unique variable created by CDC surveillance experts to help identify which cases were 
expected to complete therapy within 12 months.  
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Criteria for eligibility was determined by TB treatment guidelines and a predetermined 
algorithm based on clinical conditions, and outcomes associated with each individual case. 
Completion of therapy eligibility was coded for this project as a dichotomous predictor 
independent variable for all cases in the dataset and analysis. Completion of therapy eligibility 
was identified upon receipt of the NTSS dataset and determined as a key variable for analysis not 
originally selected in the project proposal. Experts at CDC were contacted, and I was provided 
an updated data dictionary that clearly outlined variables and methods for reporting variables in 
NTSS including the COTELIG variable. Thus, the COTELIG variable was implemented into the 
data analysis plan and coded appropriately for binomial logistic regression analysis.  
The NTSS required a two-year time frame for treatment completion updates, because 
initial therapy and treatment completion could take up to two years based on several reporting 
variables i.e. multi-drug resistance, adverse effects, and other social events where the patient’s 
treatment is delayed (CDC. 2014a). The Centers for Disease Control & Prevention’s surveillance 
branch recommended a cutoff time frame of 2014 to ensure that data were the most complete and 
omit 2015-2016 based on incompleteness. The data set was approved and received in April 2018 
to ensure that the data set is robust and complete.    
Discrepancies in Data Collection  
Discrepancies were observed in the data set from what was expected in the initial plan 
outlined in chapter 3. The completion of therapy variable contained two components with 
different CDC definitions that required careful consideration of use. The completion of therapy 
variable was described with a dichotomous outcome for a patient who completed therapy within 
a twelve-month period. In this definition the researcher must know that all patients should 
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complete therapy within 6-9 months as noted by national TB treatment guidelines (Nahid et al. 
2016). 
 This assumption was applied to the data plan and the stated variable would provide the 
best data for analysis. The NTSS database collected completion of therapy and completion of 
therapy eligibility imputed variables into the data set for all cases. A case is categorized as 
completion of therapy eligible if it meets the following criteria: 
• Patients eligible to complete therapy in ≤1 year had to have been alive at time of 
diagnosis and initiated therapy with ≥1 drug. Eligible patients did not have rifampin 
resistance; did not die in ≤1 year after initiating therapy; did not move out of the country 
in ≤1 year after initiating therapy; and did not have meningeal TB, bone or joint TB, or 
TB of the central nervous system, regardless of age; and  
• Additionally, TB patients aged 0–14 years were ineligible to complete therapy in ≤1 year 
if they had disseminated disease (defined as miliary TB, a positive TB blood culture, or a 
positive nucleic acid amplification test NAAT on a blood specimen). Patients with 
culture-negative disease, those with an unknown culture status, and those with culture-
positive disease but unknown initial drug-susceptibility test re-sults were included under 
the category of therapy of ≤1 year indicated (Report of Tuberculosis in the United States, 
2017). 
The algorithm takes into consideration site of disease, rifampin resistance, age of minors, 
whether a case moved out of country or died before therapy started or alive at diagnosis. This 
variable also was collected as a dichotomous input and recorded as (y/n) for the analysis. The 
CDC surveillance branch identifies completion of therapy eligibility as the most appropriate 
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variable for regression analysis, because there are many factors that would not allow a patient to 
complete therapy in one year which does support the best data for treatment outcomes. In 
addition, the reason therapy stopped is a variable which contains eight dispositions that show the 
final status of a case in terms of (completed, lost, refused, NOTTB, died other, unknown, and 
adverse) which describes all the reasons therapy was ended.  
The reason therapy stopped variable was coded as a dichotomous output (y/n) and was 
not restricted by the one-year CDC definition and provided the analysis of the specific variables 
that described why therapy was not completed to provide a complete picture for treatment 
completion. Thus, the dependent variable used in this data plan was completion of therapy. The 
analysis of the reason therapy stopped was based on the most complete definition and 
recommendation of the CDC data manager to determine those cases that completed treatment at 
any time during their therapy. 
 The understanding that completion of therapy and completion of therapy eligibility data 
has the most value for the big picture is noted in this investigation and described in the methods 
section. However, the reason therapy stopped is a variable that can address an alternative 
outcome for completion of therapy. The reason therapy stopped is also a good choice to look at 
odds ratios as the dependent variable controlling for completion of therapy while using 
completion of therapy eligibility as the independent variable to complete the overall picture of 
describing associations to completion of therapy within 12 months (CDC, 2016). This analysis 
strategy helped access what cases finished therapy period. Some discrepancies were found in the 
data regarding the completeness of data points within the set. Although 99 percent of the cases 
were complete, 60 percent of the cases had at least one missing data point.  
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To address this issue a multiple imputation method was run in SPSS data analysis 
software to access missing data values. Some cases were deleted from the denominator through 
data trimming which did not contain complete HIV status, and/or U.S.- born designation in the 
sub-population data set. Those cases were <1 percent of the study population and did not pose 
any significant threat to power within the design.  
A final sample size (N = 2,192) cases was produced. The multiple imputation approach 
handled the missing data points but was not necessary considering the completeness of the data 
set. Multiple imputation analysis used calculated averages and estimated calculations to impute 
missing data points. The software placed a systematic imputed dot throughout the final dataset 
all variables used in the study population to complete the analysis. Preliminary analysis was run 
with the multiple imputation data set and the trimmed cleaned final data set which produced no 
changes is outputs of associations. Multi-imputations technique was not necessary for this model, 
thus was not used in the final analysis. Primary data elements of interest were collected for age in 
categorical terms (00-14 years, 15-44 years, 45-64 years, 65+ years), and unknown status to 
satisfy analysis requirements of the model.  
Predictor variables were gender, ethnic, race, age, previous TB, stop-died, site-
pulmonary, sputum-smear, sputum-culture, site-plural, culture-lab, culture-other, nucleic acid 
amplification-test, x-ray, x-ray cavitation, TB test, sputum culture lab, homelessness, injection 
drug use, non-injection drug use, alcohol use, provider-type, primary occupation, first line drug 
resistance, resident of correctional facility, provider-type, directly observed therapy, directly 
observed therapy-site, directly observed therapy weeks, disease site,  and completion of therapy 
eligibility. The dependent variable completion of therapy was already dummy coded into 
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dichotomous variables, but the reason therapy stopped multi-categorical variable was recoded for 
logistic regression to yield associations in odds ratios of positive and negative 
correlations/associations to treatment completion.  
The sample population in this study represents all the reported cases of TB in the United 
States from 2009 thru 2014 to include both foreign-born and U.S.-born verified cases. The sub-
group of TB/HIV co-infected cases accounted for n=4,609, (5.9%) of all cases in the larger 
population (n=78,543). Non-probability sampling sample selection was used to identify all cases 
for analysis.  
Treatment of cases vary among public health programs in the U.S. and territories (CDC, 
2014a). Subsequently, only outcomes were reported in terms of categorical outcomes recorded 
under the reason therapy was stopped variable in SPSS. Outcome variables for adverse events, 
died, lost, moved, refused, other, and completed treatment were recorded and used in these 
analyses. No other outcomes were attainable from the data and final analysis were recorded as a 
dichotomous variable either completed or not-completed.    
 
Figure 1 describes the distribution of the dependent variable Completion of Therapy 
within 12 months. (COT) NEW_COT yes or no. The distribution has a negative skew -.819 and 
negative kurtosis -1.331 verifying the assumption that LR data often is not normally distributed 




             
 
Figure 1. This picture describes completion of therapy within 12 months. 
 
Table 1 describes the frequency accuracy of the predictive value of the model in 
systematically predicting outcomes for completion of therapy n=1,511 (68.9%) and does not 
complete therapy n=681 (31%). 
Table 1 
NEW_COT 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid 0 681 31.1 31.1 31.1 
1 1511 68.9 68.9 100.0 
       Total 2192 100.0 100.0  
Note: Classification Table 
 
 
Figure 2 describes the distribution of the dependent variable Reason Therapy was 
Stopped   NEW_STOPREAS yes or no. The distribution has a negative skew -1.710 and 
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negative kurtosis .926 verifying the assumption that LR data often is not normally distributed 
and should be accounted for by increasing power to 50 cases per variable. 
 
 
Figure 2. The reason therapy was stopped (new reason therapy was stopped).  
 
 
Table 2 describes the frequency accuracy of the predictive value of the model in 
systematically predicting outcomes for completion of therapy (n = 1,808) (82.59%) and does not 





                 
Frequency Percent Valid Percent Cumulative Percent 
Valid 0 384 17.5 17.5 17.5 
1 1808 82.5 82.5 100.0 
Total 2192 100.0 100.0  







             
Table 3 outlines descriptive analysis of both dependent variables (New_ completion of 
therapy & new_ reason therapy was stopped) for mean, mode, median, standard deviation, 
minimal, maximum outcome limits as well as skewness and kurtosis. The output suggests that 
both variables do not have a normal distribution and should be adjusted by increasing power to 





 NEW_COT NEW_STOPREAS 
N Valid 2192 2192 
Missing 0 0 
Mean .69 .82 
Median 1.00 1.00 
Mode 1 1 
Std. Deviation .463 .380 
Skewness -.819 -1.710 
Std. Error of Skewness .052 .052 
Kurtosis -1.331 .926 
Std. Error of Kurtosis .105 .105 
Minimum 0 0 
Maximum 1 1 
   





Table 4 represents treatment completion is defined in terms of the primary reason 
treatment was stopped (RVCT, 2015).  Health departments and private providers report through 
the NTSS database the final status of each case. Cases that completed treatment period 
(n=1,808), (82.5%) analysis were conducted using reason therapy stopped dependent variable 
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and each predictor variable under demographics, clinical diagnostics, and directly observed 
therapy. The intervention provided by individual TB control programs and private providers for 
treatment completion produced outcomes and reasons why therapy was stopped.  
Table 4 
 
Treatment Disposition Characteristics of Sample 
                Category           Total         Percent 
 
 
Therapy Reason Stop Treatment                Completed                  1,808            83.8% 
                                        Adverse             4            <1% 
      Lost              49            2.1% 
      Moved              8            <1% 
      Other   21            <1% 
      Refused  34            1.5% 
      Died   268            12.2% 
 
       
Stopped Treatment Died   Disease  64  2.9% 
      Unknown  19  <1% 
      Unrelated  92  4.2% 
                                                                                    Total Died 175  7.6% 
 
      Not Diseased  2,017  92.0% 
 
*Directly Observed Therapy   DOT Only  1,401  63.9% 
      Self-Administered 140  6.4% 
      Both DOT/SA  617  29.1% 
      Not Recorded  151  6.1% 
      Unknown  5  <1% 
 
Directly Observed Therapy in Weeks       Mean   30.93 
      Median  29.00 
      Standard Deviation 15.89  
      Range Min  0.0 
      Range Maximum 144 
 
Note: Categorical levels to describe why treatment stopped and DOT outcomes. 




             
 
Adverse Events 
Table 5 represents adverse events were not the primary reason cases did not complete 
therapy at 4 cases (<1%) was attributed to this statistic. However, lost to follow-up (n=49), 
(2.2%), and refused (n=34), (1.6%) produced the largest disparity in outcomes. The primary 
reason where treatment was stopped was among those cases who died (n=268), (12.2%). 
Consideration for TB as the primary cause in the NTSS system was used in this model provide 
the best prospective of the extent of TB disease in persons with HIV. Less than (3%) of those 
cases who died were documented due to TB disease (n=64), (2.9%).  
Table 5 
 
Completion of Therapy (COT) Characteristics of Sample 
                           Category          Total                       Percent 
 
 
    
*Completion of Therapy within 1 year Yes  1,511   68.9% 
      No  295   13.5% 
      Not Recorded 384   17.5% 
 
*Completion Eligible within 1 year  Yes  1,799   82.1% 
      No  393   17.9% 
 
*Overall Final Disposition                           Completed 1,808                         82.5% 
 Reason Therapy Was Stopped           Adverse 4   <1% 
      Died  268   12.2% 
      Lost  49   2.2% 
      Moved  8                <1% 
      Other  21   1.0% 
      Refused 34   1.6% 
       






             
Descriptive and Demographic Characteristics of the Study Sample 
The NTSS data set contained 78,543 total TB cases from 2008 thru 2014. Among total 
cases females accounted for 30,718 cases and males accounted for 47,782 cases. The overall case 
count for country of origin were, foreign-born (n=49,675, 63.2%) and US born (n=28,683, 
36.5%). HIV positive cases were extracted from the overall data set (n=4,609, 5.9%) and uses in 
the analysis model. HIV negative cases (n=54,896, 69.9%) were not used in the analysis and 
removed from the data set through trimming. Variables for other HIV categories were recorded 
as: NOTOFFRD, REFUSED, TDUNK, IND, and UNK were (8.6%, 4.1%, .4%, <1%, and 1.4%) 
of the total population respectively and were removed from calculations and the model 
denominators. 
  To determine the best sub-group for the project, the target population was selected as co-
infected cases TB/HIV. Table 3 outlined cross-tabulated cases with the US born variable to 
produce the appropriate population for the study. The analysis was describing as (U.S.-born, 
TB/HIV) which yielded the final study group of (N= 2,192) U.S.-born TB/HIV co-infected cases. 
Most of the study cases were males (n=1,581, 72.1%) and 27.8% (n=610) were females.  
All cases were U.S.-born with an ethnic breakdown non-Hispanic (n=1,887, 86.1%) and 
Hispanic (n=305, 13.9%).  Predictor variables for age in the population were described as 
characteristics in categories (0-04 years, 5-14 years, 15-24 years, 25-44 years, 45-64 years, 65+ 
years and unknown). The most significant group of cases was among the 25-44 years and the 45-
64 years age groups (n=951), (43.4%) and (n=110), (50.4%) respectively. Gender characteristics 
were outlined as male (n=1,581, 72.1%) and female (n=610, 27.8%) with male as the highest 
disparity group.  
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TB cause was defined as the patient being dead or alive at the time of diagnosis (n=179), 
(7.7%) total cases who died. Case deaths due to TB were (n=64), (2.9%) and those cases not 
related to TB were n=92 (4.2%). Non-Hispanic Blacks had the largest TB disparity of all the 
ethnic groups at (n=1,532) cases (69.9%), Whites produced the second largest case count at 
(n=314), (14.3%), Hispanics as a race were (n=305), (13.9%), American Indian (n=21), (1.0%), 
Multi-cultural as a race n=9, (<1%), and Native Hawaiian or other Pacific Islander (n=7), (<1%). 
Unknown cases yielded only two cases out of (N=2,192) completing the descriptive ethnic and 
race analysis for the study population.  
Univariate Analysis 
 
Table 6 represents univariate analysis for core demographic variables. Sub-population 
variables to describe the final sample size including criterion variables for co-infection including 
U.S.-born, alive at time of diagnosis, HIV positive, and active TB case. HIV positive cases 
(n=2,192), (100%) gender (n=1,581) males, females (n=610), (85% and 28%). Ethnic groups 
were categorized into American Indian (n=21), Asian (n=4), Black (n=1,532), Native Hawaiian 
Pacific Islander (n=7), White (n=314), Hispanic as a Race(n=30), and Multiple Race (n=9) 
respectively. Age was categorized into six groups including (00-04) years, (05-14) years, (15-24) 
years, (25-44) years, (45-64) years, and (65+) years Age groups 45-64 years, n=1.104 and 65+ 
years, (n=951) provided the most significant populations identified in the analysis at (50%, and 
43%). Other age categories combined were (<5%). Cause of TB was described for a case is the 
diagnosis at death was noted on the death record. TB cause (n=64), (2.9%) of the total population 




             
Table 6 
 
Descriptive and Demographic Characteristics of Sample 
              Category            Total   Percent 
Sample size        2,192            100%                 
U.S.-Born       2,192   100% 
HIV positive                                                                           2,192   100%  
 
Gender     Male  1,581     85.1% 
      Female 610          27.8% 
Previous TB       148   6.3% 
 
Ethnic Groups       Non-Hispanic 1,887   86.1% 
      Hispanic 305   13.9% 
 
Race      AMID  21   1.0% 
                                                                        ASIAN 4   023% 
      BLACK 1,532   69.9% 
      NAHAW 7   <1 % 
      WHITE 314   14.3% 
      RACEHISP 305   13.9%  
      MULT  9   <1% 
Age Groups     00-04 years     3   <1% 
      05-14 years 3   <1% 
                                                                        15-24 years     64   2.9% 
       25-44 years 951   43.3% 
      45-64 years 1,104   50.4% 
      65+ years 67   3.1% 
 
TB Cause     Yes  64   2.9% 
      No  92   4.2% 
      Unknown 19   <1% 
______________________________________________________________________________ 
Note: Demographic variables and categorical designations for race, age, TB cause. 
 
 
Table 7 described the sample size subset of the population through deductive analysis 
provided a dataset (N=2,192) whereas key clinical variables were collected that support the 
project model and risk factors important to clinicians for treatment completion (CDC, 2016). Site 
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of disease for pulmonary were (n=1,767), (80.6%) and not pulmonary (n=425), (19.4%). 
Laboratory diagnostics for smear status n=781 positive and n=1,150 negative. Providers recoded 
a not done status n=3. Nucleic acid amplification test positive (n=603), (27.5%), negative 
(n=199), (9.1%), not done (n=1,003), (45.8%), unknown (n=13), (<1%), and indeterminate 
(n=2), (<1%).  The HIV status of confirmed cases is described by diagnostic outcomes for X-ray 
cavitation evaluation in terms of disease severity. X-ray cavitation (n=323), (13.8%) no 
cavitation (n=1,423), (60.8%).  
Table 7 
 
Clinical Descriptive Characteristics of Sample 
                          Category Total            Percent 
Sample size        2,192            100% 
*Positive Culture Final Disposition  Yes  1,205   55.0% 
  
Site Pulmonary     Yes  1,767   80.6% 
       
Site Plural     Yes  104   4.7% 
      No  2,080   95.3% 
 
Specimen Smear    Negative 1,150   52.5% 
      Positive 781   35.6% 
      Not Done 257   11.7% 
 
Sputum Culture    Positive 1,205   55.0% 
      Not Done 273   12.5% 
      Negative 709   32.3% 
  
Nucleic Acid Amplification Test  Positive 603   27.5% 
      Negative 199   9.1% 
      Not Done 1,003   45.8% 
      Unknown 13   <1% 
      Indeterminate 2   <1% 
                           Category          Total                       Percent 
 
X-ray Cavitation     Yes  306   14.0% 
      No  1,330   60.7% 
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                                                                                                                      (table continues) 
  
      Unknown 11   <1% 
      Not Recorded 545   24.9% 
           
TB-Test     Positive 747   34.1% 
      Negative 516   23.5% 
      Not Done 864   39.4% 
      Unknown 51   2.3% 
 
HIV-Stat     Positive 2192   100% 
 _______________________________________________________________________ 
Note: Key clinical variables necessary to determine completion of therapy. 
 
 
Table 8 describes demographic characteristics for homeless (n=458), (20.9%), long-term 
care facility (n=65), (3.8%), and primary occupation unemployed (n=1,048), (48.5%) not seeking 
work (n=210), (9.6%), not recorded (n=45,5) (20.8%), health care worker, migrant worker, 
retired, and unknown collectively (<5%).  
Table 8 
Demographic Characteristics of Sample 
                Category           Total         Percent 
Homelessness     Yes                         458             20.9% 
      No   1,721  78.5% 
      Unknown  12  <1% 
       
Correctional Institution   Yes   178  8.1% 
      No   2,005  91.5% 
       
Long-Term Care Facility   Yes   65  3.0% 
      No   2124  96.9% 
      Unknown  2  <1% 
Primary Occupation    Correctional  3  <1% 
      Health Care Worker 29  1.3% 
      Migrant Worker 8  <1% 
      Not Seeking Work 210  9.6% 
      Other   391  17.8% 
      Retired  32  1.5% 
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                                                                                                                                 (table continues) 
 
 
      Unemployed  1,048  48.8% 
      Unknown  16  <1% 
 
 
      Not Recorded  445  19.7% 
Note: Second level categorical demographic variables selected for analysis. 
 
Table 9 describes substance abuse in terms of intravenous drug use (n=213), (9.7%), non-
intravenous drug use (n=727), (33.2%), and alcohol use (n=585), (26.7%) of the sample 
population.  
Table 9 
Demographic Characteristics of Sample 
                Category           Total         Percent 
 
 
Intravenous Drug Use    Yes   213  9.7% 
      No   1,954  89.1% 
      Unknown  25  1.1% 
 
Non-Intravenous Drug Use   Yes   727  33.2% 
      No   1,439  65.6% 
      Unknown  25  1.1% 
 
Alcohol     Yes   585  26.7% 
      No   1,583  72.2% 
      Unknown  24  1.1% 
 
 




             
Table 10 describes provider disposition in terms of managing TB cases. Health 
department (n=1,397), (63.7%), Both HD/PRI (n=254), (11.6%), PRI/OTH (n=466), (21.3%), 
not recorded (n=65), (3.0%) and unknown (n=10), (0.5%). 
 
Table 10 
Provider Disposition Characteristics of Sample 
                  Category             Total            Percent 
 
Provider Disposition                                       Health Department 1,397             63.7% 
                 Both HD/PRI    254  11.6% 
      PRI/OTHER      466  21.3% 
      Unknown  10  <1% 
      Not Recorded  65  3.0% 
 
Note: First level designations for delivery of services.        Total    2192     100%  
 
 
Table 11 describes drug resistance among cases multi-drug resistance (n=14), (0.6%), no 
extensively-drug resistant cases were observed. First line drug resistance (n=15.8) (7.2%) not 
first line drug resistant (n=2,034), (92.8%).  
Table 11 
Clinical Descriptive Characteristics of Sample 
                           Category          Total                       Percent 
 
Multi-Drug Resistant               Yes  14   0.6% 
      No  1,544   70.4% 
      Not Recorded 624   28.5% 
 
First Line Drug Resistant   No  2,034   92.8% 
      Yes  158   7.2% 
Note: First level variables used in completion of therapy algorithm.   
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Table 12 show all independent variables that have a significant Pearson’s Correlated to 
the dependent variable new reason therapy stopped and are statistically significant at the 
(p=0.01) and (p=0.05) levels. Significant predictor variables were used in the binomial logistic 
regression on both levels (enter, forward LR).    
Table 12 
Correlations New Reason Therapy Was Stopped                                     
   Variable                                                    Correlation                                  Sig.   
______________________________________________________________________________    
New Intravenous Drug Use       .686**   .000     
______________________________________________________________________________
New Completion of Therapy Eligible             -.639**   .000   
______________________________________________________________________________ 
New Completion of Therapy                           -.686**   .000   
______________________________________________________________________________
New Previous TB                                      -.043*                                     .000 
______________________________________________________________________________
New TB Test                                       .124*                                      .000                 
______________________________________________________________________________
New Long-Term          -.047*               .000                     
______________________________________________________________________________
New Occupation      -.101**                                   .000         
______________________________________________________________________________
New Initial INH       -.067*                                      .000    
______________________________________________________________________________
New Initial PZA                                               .080**   .000       
______________________________________________________________________________
New Stopped Treatment Died                         -.376**     .000    
______________________________________________________________________________
New Multi-Drug Resistant     -.069**                                   .000   
 
Note: Correlation is significant at the 0.01 level (2-tailed). Correlation is significant at the 0.05 
level (2-tailed).  
  
 
 Table 13 show all independent variables that have a significant Pearson’s Correlated to 
the dependent variable New Completion of Therapy and are statistically significant at the 
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(p=0.01) and (p=0.05) levels. Significant predictor variables were used in the binomial logistic 
regression on both levels (enter, forward LR).   
Table 13 
Correlations New Completion of Therapy  
______________________________________________________________________ 
   Variable                                                    Correlation                                 Sig.   
______________________________________________________________________________    
New Intravenous Drug Use            .066**             .000     
______________________________________________________________________________
New Completion of Therapy Eligible             -.555**             .000   
______________________________________________________________________________ 
New Reason Therapy Stopped                        -.686**             .000   
______________________________________________________________________________
New Site Pulmonary                                      .065*                                    .002 
______________________________________________________________________________
New Site Plural                                      -.045*               .035                 
______________________________________________________________________________
New TB Test                    -.100*              .000                     
______________________________________________________________________________
New Occupation       -.045**                                 .034         
______________________________________________________________________________ 
New Initial INH                                                .087**   .000       
______________________________________________________________________________
New Initial PZA                                                .082**   .000       
______________________________________________________________________________ 
New Moved                                                      -.078**     .000    
______________________________________________________________________________
New Stopped Died                                            -.258**     .000    
______________________________________________________________________________ 
NEW_MDR          -.119**                                 .000   
 
NEW_FIRSTLINE        -.057**                                 .000   
 







             
 Evaluation of Statistical Assumptions (Binary Logistic Regression) Statistical assumption 
for binary logistic regression has unique components that drive the success of analysis and 
should be addressed to ensure that potential problems are eliminated or reduced (Field, 2009). 
Each assumption was addressed individually in terms of met and not met to qualify overall 
analysis methods.  
• Assumption #1 the design should have one dichotomous dependent variable. 
(Assumption met). 
• Assumption #2 the design should have one or more independent variable measured on the 
continuous or nominal scale. (Assumption met). 
• Assumption #3 the study design should have independence of observations and the 
categories of the dichotomous dependent variable and all you’re nominal. Independent 
variables should be mutually exclusive and exhaustive. (Assumption met). 
• Assumption # 4 the design should have 15 cases minimum for the independent variable. 
(Assumption met). 
• Assumption # 5 the data needs to have a linear relationship among the continuous. 
Independent variables and the logit transformation of the dependent variable. 
(Assumption met). No continuous variables were selected for analysis.  
• Assumption # 6 the data must not show Multicollinearity. (Assumption met). 
• Assumption # 7 the data set should have no significant outliers, high leverage points or 





             
Statistical Analysis Findings 
Research Question 1 
What relationship between and individual’s ethnic/racial group membership among U.S.-
born non-Hispanics with an HIV/TB co-infection and the likelihood of completion of therapy. 
Tables 1-11 set the framework to determine the impact in answering the research question. Upon 
analysis descriptive outcomes provided the data, power, and variables that formed the foundation 
to determine which specific variables were correlated to both outcomes of completion of therapy 
and the reason therapy stopped. Tables 12 and 13 describe all key variables as they relate to both 
dependent variables which suggest that ethnic/racial group membership of U.S.-born non-
Hispanic co-infected persons is not strongly correlated with either completion of therapy or the 
reasons therapy stopped.  Based on the described outcomes, acceptance of the null-hypothesis is 
required because analysis suggest there is no association between race/ethnicity and completion 
of therapy for persons with co-infection in the United States. 
 Table 14 describes the completion of therapy in 12 months classification table which 
determines the predictive ability of the regression model to accurately predict dichotomous 









             
Table 14   
Completion of therapy (COT) SPSS (Enter)                                          
Classification Table 
 
                                                                                
Observed                                      NEW COT           Predicted                 Correct        Percentage 
 
Step 0                                                 0                             0                          681                 0 
                       
                                       1                             0                          1,511              100.0 
Overall Percentage                                                                                                               68.9 




 Table 15 describes the omnibus test for model fit to determine the significance of model 
improvement from the null-model prediction. Statistical significance p-value (<.001), chi-square 
(1307.843) which validates an improvement in the overall model  
Table 15 
 
Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 1307.843 47 .000 
Block 1307.843 47 .000 
Model 1307.843 47 .000 
Note: Stepwise regression analysis of model fit. 
 
 
Table 16 describes the pseudo R-square Nagelkerke test which describes the proportion 
of variance in the predictor variables (.633) or 63 percent of the variance in the dependent 
variable is explained by the selection of independent variables placed in the final model.  
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Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 1408.658a .449 .633 
a. Estimation terminated at iteration number 20 because maximum iterations has been 
reached. Final solution cannot be found. 
 
Table 17 describes the Hosmer and Lemeshow goodness of fit chi-square=11.235, df=8, 
and p-value=.189 which is greater than p-value=.005 and is conformation that model was 
improved by variables selected for the model and is a goodness of fit. 
Table 17 
Hosmer and Lemeshow Test 
Step     Chi-square  df   Sig. 
  1                                                           11.135                       8                                 .189 
______________________________________________________________________________ 
Note: Goodness of fit metric, p-value must be (>.005). 
 
Table 18 describes the logistic regression stepwise contingency table for the Hosmer and 
Lemeshow test for steps one through ten improving the predictive ability of the model to the 









             
Table 18 
Contingency Table for Hosmer and Lemeshow Test 
 
NEW_COT = 0 NEW_COT = 1 





1 219 219.000 0 .000 219 
2 201 204.178 18 14.822 219 
3 92 77.302 127 141.698 219 
4 30 43.109 187 173.891 217 
5 31 34.296 189 185.704 220 
      
6 32 28.956 188 191.044 220 
7 25 25.006 203 202.994 228 
8 20 21.222 200 198.778 220 
9 20 17.675 209 211.325 229 
10 11 10.257 190 190.743 201 
Note: Stepwise contingency table predicted outcomes of final regression model.  
 
 
Table 19 describes the completion of therapy in 12 months classification table which 
determines the predictive ability of the regression model to accurately predict dichotomous 




                                                                                
Observed                                      NEW COT           Predicted                 Correct        Percentage 
 
Step 0                                                 0                            434                       247                63.7 
                       
                                       1                            26                         1,485             98.3 
Overall Percentage                                                                                                              87.5 





             
Table 20 displays all variables not included in the final logistic regression equation. Each 
variable may be significant on its own in terms of completion of therapy and is noted with a p-
value (<.005) but were not used to identify correlations with dependent variables.  
Table 20 
 
Variables not in the Equation 
 Score df Sig. 
Step 0 
 
Variables NEW_IDU 9.545 1 .002 
NEW_COTELIG 674.855 1 .000 
NEW_PREVTB 12.524 1 .000 
NEW_SITEPULM 9.187 1 .002 
NEW_SITEPLR 4.442 1 .035 
NEW_TBTEST 21.915 1 .000 
NEW_OCCUPATN 4.517 1 .034 
NEW_INITINH 16.428 1 .000 
NEW_INITPZA 14.714 1 .000 
NEW_MOVED 13.324 1 .000 
NEW_STOPDIED 146.274 1 .000 
NEW_MDR 31.263 1 .000 
NEW_FIRSTLINE 7.084 1 .008 
RACEHISP 10.379 6 .110 
RACEHISP (1) 1.430 1 .232 
RACEHISP (2) 1.806 1 .179 
RACEHISP (3) 2.264 1 .132 
RACEHISP (4) 6.586 1 .010 
RACEHISP (5) .755 1 .385 
RACEHISP (6) .020 1 .886 
ETHNIC (1) 6.586 1 .010 
STOPREAS 1032.977 6 .000 
STOPREAS (1) 8.891 1 .003 
STOPREAS (2) 1032.977 1 .000 
STOPREAS (3) 677.466 1 .000 
STOPREAS (4) 111.207 1 .000 
STOPREAS (5) 17.815 1 .000 
STOPREAS (6) 47.045 1 .000 
OCCUPATN 7.808 4 .099 
OCCUPATN (1) .575 1 .448 
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         (table continued) 
 
OCCUPATN (2) 
.451 1 .502 
OCCUPATN (3) 2.782 1 .095 
OCCUPATN (4) 4.517 1 .034 
PROVTYPE 90.019 4 .000 
PROVTYPE (1) .583 1 .445 
PROVTYPE (2) 2.116 1 .146 
PROVTYPE (3) 76.341 1 .000 
PROVTYPE (4) 73.940 1 .000 
DOT 46.885 4 .000 
DOT (1) .646 1 .421 
DOT (2) 6.950 1 .008 
DOT (3) 1.170 1 .279 
DOT (4) 37.646 1 .000 
DOTSITE 24.884 4 .000 
DOTSITE (1) 1.030 1 .310 
DOTSITE (2) 3.321 1 .068 
DOTSITE (3) 13.919 1 .000 
DOTSITE (4) 7.731 1 .005 
DIS_SITE 19.852 2 .000 
DIS_SITE (1) 8.672 1 .003 
DIS_SITE (2) 7.173 1 .007 
AGE3 7.959 5 .159 
AGE3(1) 1.354 1 .245 
AGE3(2) 1.792 1 .181 
AGE3(3) .482 1 .488 
AGE3(4) 1.778 1 .182 
AGE3(5) .308 1 .579 
Note: Residual Chi-Squares are not computed because of redundancies. 
 
Table 21 describes all variables retained in the equation and are evaluated in the analysis 
one variable at a time while controlling for other variables in the model to determine the final 
model configuration. A binomial logistic regression analysis was performed to ascertain the 
effects of : NEW_IDU, NEW_COTELIG, NEW_PREVTB, NEW_SITEPULM, 
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NEW_SITEPLR, NEW_TBTEST, NEW_OCCUPATN, NEW_INITINH, NEW_INITPZA, 
NEW_MOVED, NEW_STOPDIED, NEW_MDR, NEW_FIRSTLINE, RACEHISP, 
STOPREAS, OCCUPATN, PROVTYPE, DOT, DOTSITE, DIS_SITE,  and AGE3 on the 
likelihood that cases complete therapy. Chi-Square = 1307.843, df =47, p<.0005. The model 
explained 63.3 percent (Nagelkerke R square) of the variance in COT and correctly classified 
87.5 percent of cases.  Sensitivity was 63.7 percent and specificity were 98.5 percent. Of the 
twenty-one predictor variables only five were statistically significant: COTELIG, PREVTB, 
INITINH, MOVED, and DIS-SITE 1 (as shown in Table 16). Cases that were COTELIG were 
5.4 times more likely to complete therapy within 12 months. Individuals that took INH as a part 
of the initial treatment regimen for at least two weeks increase their odds of COT by 5.9 times. 
Cases having a previous diagnosis of TB decreases their odds of completing therapy -2.3 times. 
Having moved outside of normal reporting jurisdiction decreases odds of COT 42.5 times. Cases 
having pulmonary and plural TB decreases their likelihood of COT decreased by 45.9 percent.   
Based on analysis, the null hypothesis is accepted because no demographic variables were 
retained in the final model to include ethnicity/race, gender, and age which are key first level 
independent variables. Alternatively, the completion of therapy eligibility and several clinical 
















Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 






NEW_IDU -.409 .226 3.262 1 .071 .664 .426 1.035 
NEW_COTELI 1.696 .245 47.92 1 .000 5.453 3.375 8.811 
NEW_PREVT -.609 .269 5.135 1 .023 .544 .321 .921 
NEW_SITEPU 1.042 .819 1.620 1 .203 2.836 .570 14.120 
NEW_SITEPL 22.578 25942.59 .000 1 .999 .000 .000 . 
NEW_TBTEST .057 .147 .150 1 .698 1.059 .794 1.411 
NEW_OCCUP -.731 .467 2.449 1 .118 .481 .193 1.203 
NEW_INITIN 1.790 .553 10.44 1 .001 5.989 2.025 17.715 
NEW_INITPZ .019 .416 .002 1 .964 1.019 .451 2.303 
NEW_MOVED -.858 .216 15.86 1 .000 .424 .278 .647 
NEW_STOPDI 8.025 5748.015 .000 1 .999 3057.404 .000 . 
NEW_MDR 20.382 8784.099 .000 1 .998 .000 .000 . 
NEW_FIRSTLI -.138 .253 .298 1 .585 .871 .531 1.430 
RACEHISP   4.496 6 .610    
RACEHISP (1) .119 .831 .021 1 .886 1.127 .221 5.748 
RACEHISP (2) 20.773 18412.48 .000 1 .999 1.05E+9 .000  
RACEHISP (3) -.312 .213 2.136 1 .144 .732 .482 1.112 
RACEHISP (4) -.429 .268 2.553 1 .110 .651 .385 1.102 
RACEHISP (5) -1.365 .927 2.169 1 .141 .255 .041 1.571 
RACEHISP (6) 16.541 4889.737 .000 1 .997 1.051E+
9 
.000 . 
STOPREAS   .000 6 1.000    
STOPREAS (1) 12.988 20922.55
3 
.000 1 1.000 437117.5
99 
.000 . 
STOPREAS (2) 35.886 7322.136 .000 1 .996 3.85E+1
5 
.000 . 
STOPREAS (3) 6.293 7966.911 .000 1 .999 540.716 .000 . 
STOPREAS (4) 12.762 9191.880 .000 1 .999 348587.2 .000 . 
STOPREAS (5) -1.312 12882.49 .000 1 1.000 .269 .000 . 
STOPREAS (6) 2.429 10570.57 .000 1 1.000 11.351 .000 . 
OCCUPATN   2.435 3 .487    
OCCUPATN1 -1.399 .998 1.968 1 .161 .247 .035 1.743 
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            (table continued)  




















OCCUPATN3 -.570 .528 1.168 1 .280 .565 .201 1.590 
PROVTYPE   5.310 4 .257    
PROVTYPE1  .719 1.049 .469 1 .493 2.052 .262 16.050 
PROVTYPE 2 .434 .950 .209 1 .648 1.544 .240 9.945 
PROVTYPE 3 .678 .935 .527 1 .468 1.970 .315 12.309 
PROVTYPE 4 .305 .943 .104 1 .747 1.356 .214 8.611 
DOT   8.701 4 .069    
DOT 1 11.562 2181.13 .000 1 .996 .000 .000 . 
DOT 2 13.687 2181.192 .000 1 .995 .000 .000 . 
DOT 3 13.328 2181.192 .000 1 .995 .000 .000 . 
DOT 4 13.224 2181.192 .000 1 .995 .000 .000 . 
DOTSITE   9.909 4 .042    
DOTSITE 1 -1.642 1.272 1.668 1 .196 .194 .016 2.339 
DOTSITE 2 -.431 1.333 .104 1 .747 .650 .048 8.860 
DOTSITE 3 -1.494 1.315 1.291 1 .256 .225 .017 2.954 
DOTSITE 4 -.411 1.342 .094 1 .759 .663 .048 9.199 
DIS_SITE   14.53 2 .001    
DIS_SITE 1 -.615 .186 10.98 1 .001 .541 .376 .778 
DIS_SITE 2 .808 .844 .917 1 .338 2.244 .429 11.741 
AGE3   6.611 5 .251    
AGE3(1) 18.909 23021.92 .000 1 .999 160E+8 .000 . 
AGE3(2) -.264 .620 .181 1 .670 .768 .228 2.590 
AGE3(3) -.471 .497 .900 1 .343 .624 .236 1.653 
AGE3(4) -.179 1.607 .012 1 .912 .836 .036 19.523 
AGE3(5) -.113 .498 .052 1 .820 .893 .336 2.371 
Constant 23.229 7640.103 .000 1 .998 .000   
Note: Variable(s) entered on step 1: NEW_IDU, NEW_COTELIG, NEW_PREVTB, 
NEW_SITEPULM, NEW_SITEPLR, NEW_TBTEST, NEW_OCCUPATN, 
NEW_INITINH, NEW_INITPZA, NEW_MOVED, NEW_STOPDIED, NEW_MDR, 
NEW_FIRSTLINE, RACEHISP, STOPREAS, OCCUPATN, PROVTYPE, DOT, 




             
Table 22 describes the completion of therapy in 12 months classification table which 
determines the predictive ability of the regression model to accurately predict dichotomous 
outcomes of the dependent variable overall 68.9 percent prediction for cases in the model. 
Table 22 
Completion of Therapy Variable (COT) SPSS (Forward LR) 
Classification Table 
 
                                                                                
Observed                                      NEW COT           Predicted                 Correct        Percentage 
 
Step 0                                                 0                             0                          681                 0 
                       
                                       1                             0                          1,511              100.0 
Overall Percentage                                                                                                               68.9 
Note: Constant is included in the model cut value is .500 
 
Table 23 describes the pseudo R-square Nagelkerke test which describes the proportion 
of variance in the predictor variables (.633) or 63 percent of the variance in the dependent 




















             
Table 23 
Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 1408.658a .449 .633 
 
Note: Estimation terminated at iteration number 20 because maximum iterations have been 
reached. Final solution cannot be found. 
 
 
Table 24 displays all variables not included in the final logistic regression equation. Each 
variable may be significant on its own in terms of completion of therapy and is noted with a p-
value (<.005) but were not used to identify correlations with dependent variables.  
 
Table 24 
Variables not in the Equation 
 Score df Sig. 
Step 0 Variables NEW_IDU 9.545 1 .002 
NEW_COTELIG 674.855 1 .000 
NEW_PREVTB 12.524 1 .000 
NEW_SITEPULM 9.187 1 .002 
NEW_SITEPLR 4.442 1 .035 
NEW_TBTEST 21.915 1 .000 
NEW_OCCUPATN 4.517 1 .034 
NEW_INITINH 16.428 1 .000 
NEW_INITPZA 14.714 1 .000 
NEW_MOVED 13.324 1 .000 
NEW_STOPDIED 146.274 1 .000 
NEW_MDR 31.263 1 .000 
NEW_FIRSTLINE 7.084 1 .008 
RACEHISP 10.379 6 .110 
RACEHISP (1) 1.430 1 .232 
RACEHISP (2) 1.806 1 .179 
RACEHISP (3) 2.264 1 .132 
RACEHISP (4) 6.586 1 .010 
RACEHISP (5) .755 1 .385 
RACEHISP (6) .020 1 .886 
ETHNIC (1) 6.586 1 .010 
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 (table continued) 
OCCUPATN 7.808 4 .099 
OCCUPATN (1) .575 1 .448 
OCCUPATN (2) .451 1 .502 
OCCUPATN (3) 2.782 1 .095 
OCCUPATN (4) 4.517 1 .034 
PROVTYPE 90.019 4 .000 
PROVTYPE (1) .583 1 .445 
PROVTYPE (2) 2.116 1 .146 
PROVTYPE (3) 76.341 1 .000 
PROVTYPE (4) 73.940 1 .000 
DOTSITE 24.884 4 .000 
DOTSITE (1) 1.030 1 .310 
DOTSITE (2) 3.321 1 .068 
DOTSITE (3) 13.919 1 .000 
DOTSITE (4) 7.731 1 .005 
DIS_SITE 19.852 2 .000 
DIS_SITE (1) 8.672 1 .003 
DIS_SITE (2) 7.173 1 .007 
AGE3 7.959 5 .159 
AGE3(1) 1.354 1 .245 
AGE3(2) 1.792 1 .181 
AGE3(3) .482 1 .488 
AGE3(4) 1.778 1 .182 
AGE3(5) .308 1 .579 
DOT 46.885 4 .000 
DOT (1) .646 1 .421 
DOT (2) 6.950 1 .008 
DOT (3) 1.170 1 .279 
DOT (4) 37.646 1 .000 
STOPREAS 1032.977 6 .000 
STOPREAS (1) 8.891 1 .003 
STOPREAS (2) 1032.977 1 .000 
STOPREAS (3) 677.466 1 .000 
STOPREAS (4) 111.207 1 .000 
STOPREAS (5) 17.815 1 .000 
STOPREAS (6) 47.045 1 .000 
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Table 25 describes the logistic regression stepwise contingency table for the Hosmer and 
Lemeshow test for steps 1 through 8 improving the predictive ability of the model to the 
expected values in the final model.  
Table 25 
 
Contingency Table for Hosmer and Lemeshow Test 
 
NEW_COT = 0 NEW_COT = 1 
Total Observed Expected Observed Expected 
Step 1 1 350 350.000 0 .000 350 
2 34 34.000 0 .000 34 
3 297 297.000 1511 1511.000 1808 
Step 2 1 273 273.000 0 .000 273 
2 176 176.000 55 55.000 231 
3 232 232.000 1456 1456.000 1688 
Step 3 1 291 291.000 0 .000 291 
2 158 158.000 55 55.000 213 
3 36 35.018 99 99.982 135 
4 196 196.982 1357 1356.018 1553 
Step 4 1 295 295.000 0 .000 295 
2 156 155.316 55 55.684 211 
3 42 41.712 109 109.288 151 
4 188 188.972 1347 1346.028 1535 
Step 5 1 299 299.000 0 .000 299 
2 157 155.729 59 60.271 216 
3 37 37.233 105 104.767 142 
4 42 40.186 176 177.814 218 
5 32 31.185 214 214.815 246 
6 114 117.667 957 953.333 1071 
Step 6 1 155 155.000 0 .000 155 
2 216 216.000 0 .000 216 
3 97 96.261 83 83.739 180 
4 67 65.552 257 258.448 324 
5 32 32.915 214 213.085 246 
6 114 115.273 957 955.727 1071 
Step 7 1 156 156.000 0 .000 156 
2 216 216.000 0 .000 216 
3 97 96.216 83 83.784 180 
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   (table continued) 
4 67 65.295 257 258.705 324 
5 31 32.300 214 212.700 245 
6 114 115.189 957 955.811 1071 
Step 8 1 179 179.000 0 .000 179 
2 218 219.348 3 1.652 221 
3 99 97.157 168 169.843 267 
4 41 39.366 173 174.634 214 
5 40 41.628 264 262.372 304 
6 104 104.501 903 902.499 1007 




Table 26 describes the completion of therapy in 12 months classification table which 
determines the predictive ability of the regression model to accurately predict dichotomous 






NEW_COT Percentage Correct 
 0 1  
Step 1 NEW_COT 0 384 297 56.4 
1 0 1511 100.0 
Overall Percentage   86.5 
Step 2 NEW_COT 0 449 232 65.9 
1 55 1456 96.4 
Overall Percentage   86.9 
Step 3 NEW_COT 0 449 232 65.9 
1 55 1456 96.4 
Overall Percentage   86.9 
 
Step 4 
NEW_COT 0 451 230 66.2 
1 55 1456 96.4 
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 (table continued) 
Overall Percentage   87.0 
Step 5 NEW_COT 0 415 266 60.9 
1 19 1492 98.7 
Overall Percentage   87.0 
Step 6 NEW_COT 0 420 261 61.7 
1 19 1492 98.7 
Overall Percentage   87.2 
Step 7 NEW_COT 0 421 260 61.8 
1 19 1492 98.7 
Overall Percentage   87.3 
Step 24 NEW_COT 0 430 251 63.1 
1 25 1486 98.3 
Overall Percentage   87.4 
Note: The cut value is .500 
 
Research Question 2 
Is there a relationship/association for completing therapy among TB/HIV co-infected 
U.S.-born non-Hispanics with an HIV/TB co-infection moderated by completion of therapy 
eligibility?   In Table 26, a binomial logistic regression (Forward LR) analysis was performed to 
ascertain the effects of: NEW_IDU, NEW_COTELIG, NEW_PREVTB, NEW_SITEPULM, 
NEW_SITEPLR, NEW_TBTEST, NEW_OCCUPATN, NEW_INITINH, NEW_INITPZA, 
NEW_MOVED, NEW_STOPDIED, NEW_MDR, NEW_FIRSTLINE, RACEHISP, 
STOPREAS, OCCUPATN, PROVTYPE, DOT, DOTSITE, DIS_SITE, and AGE3 on the 
likelihood that cases complete therapy. Chi-Square = 1260.996, df =14, p<.0005.  
The model explained 61.6 percent (Nagelkerke R square) of the variance in COT and 
correctly classified 87.4 percent of cases.  Sensitivity was 63.1 percent and specificity 98.3 
percent. Of the twenty-one predictor variables only five were statistically significant: COTELIG, 
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PREVTB, INITINH, MOVED, and DIS-SITE 1 (as shown in Table 16). Cases that were 
COTELIG were 5.1 times more likely to complete therapy within 12 months. Individuals that 
took INH as a part of the initial treatment regimen for at least two weeks increase their odds of 
COT by 5.3 times. Cases having a previous diagnosis of TB decreases their odds of completing 
therapy -3.3 times. Having moved outside of normal reporting jurisdiction decreases odds of 
COT 38.3 times. Cases having pulmonary and plural TB decreases their likelihood of COT 
decrease by 48.5 percent.  Based on the analysis, the null hypothesis is rejected because 
completion of eligibility and clinical variables were retained in the final model which indicated 
correlations and well as strong associations to completion of therapy within 12 months.  Analysis 
show a relationship/association for completing therapy among TB/HIV co-infected U.S.-born 
non-Hispanics with an HIV/TB co-infection moderated by completion of therapy eligibility. The 
alternative hypothesis is accepted.  So how does all this impact your hypothesis.   
Table 26 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 
95% C.I. for 
EXP(B) 
Lower Upper 
Step 1a STOPREAS   .000 6 1.000    
STOPREAS1 .000 2145.618 .000 1 1.000 1.000 .000 . 
STOPREAS2 22.830 6892.573 .000 1 .997 8215.522 .000 . 
STOPREAS3 .000 7316.793 .000 1 1.000 1.000 .000 . 
STOPREAS4 .000 8970.866 .000 1 1.000 1.000 .000 . 
STOPREAS5 .000 1573.730 .000 1 1.000 1.000 .000 . 
STOPREAS6 .000 1115.041 .000 1 1.000 1.000 .000 . 
Constant 21.203 6892.573 .000 1 .998 .000   
          
 NEW_COTE 2.004 .196 10.116 1 .000 7.417 5.047 10.899 
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STOPREAS1 -.118 2123.517 .000 1 1.000 .889 .000 . 
STOPREAS2 22.922 6761.689 .000 1 .997 9010.150 .000 . 
STOPREAS3 1.771 7185.613 .000 1 1.000 5.876 .000 . 
STOPREAS4 -.063 8836.621 .000 1 1.000 .938 .000 . 
STOPREAS5 .049 1540.182 .000 1 1.000 1.051 .000 . 
STOPREAS6 .204 1076.039 .000 1 1.000 1.226 .000 . 
Constant 23.089 6761.689 .000 1 .997 .000   
Step 3c NEW_COTE 2.022 .198 10.219 1 .000 7.551 5.122 11.132 
NEW_MOV
E 
-.880 .202 19.025 1 .000 .415 .279 .616 
STOPREAS   .000 6 1.000    
STOPREAS1 .182 2092.541 .000 1 1.000 1.200 .000 . 
STOPREAS2 22.941 6717.054 .000 1 .997 9182.051 .000 . 
STOPREAS3 1.755 7142.438 .000 1 1.000 5.786 .000 . 
STOPREAS4 -.006 8779.714 .000 1 1.000 .994 .000 . 
STOPREAS5 -.024 1534.112 .000 1 1.000 .976 .000 . 
STOPREAS6 .318 1069.123 .000 1 1.000 1.375 .000 . 
Constant 23.033 6717.054 .000 1 .997 .000   
Step 
4d 
NEW_COTE 2.032 .199 10.366 1 .000 7.631 5.167 11.270 
NEW_INITI 1.733 .447 15.038 1 .000 5.657 2.356 13.581 
NEW_MOV
E 
-.884 .203 19.016 1 .000 .413 .277 .615 
STOPREAS   .000 6 1.000    
STOPREAS1 .113 2091.550 .000 1 1.000 1.120 .000 . 
STOPREAS2 22.904 6673.115 .000 1 .997 8852.982 .000 . 
STOPREAS3 1.712 7098.569 .000 1 1.000 5.543 .000 . 
STOPREAS4 -.052 8737.394 .000 1 1.000 .949 .000 . 
STOPREAS5 -.094 1536.052 .000 1 1.000 .910 .000 . 
STOPREAS6 .314 1061.381 .000 1 1.000 1.368 .000 . 
Constant 24.706 6673.115 .000 1 .997 .000   
Step 5e NEW_COTE 1.884 .222 71.862 1 .000 6.581 4.257 10.174 
NEW_INITI 1.663 .450 13.657 1 .000 5.277 2.184 12.749 
NEW_MOV
E 
-.912 .205 19.832 1 .000 .402 .269 .600 
DIS_SITE   11.909 2 .003    
DIS_SITE (1) -.605 .176 11.832 1 .001 .546 .387 .771 
DIS_SITE (2) -.162 .187 .752 1 .386 .850 .589 1.227 
STOPREAS   .000 6 1.000    
STOPREAS1 .051 2088.381 .000 1 1.000 1.052 .000 . 
STOPREAS) 22.961 6638.556 .000 1 .997 9370.675 .000 . 
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       (table continued) 
 
STOPREAS3 1.628 7065.224 .000 1 1.000 5.093 .000 . 
STOPREAS4 -.038 8699.043 .000 1 1.000 .962 .000 . 
STOPREAS5 -.174 15379.69
0 
.000 1 1.000 .840 .000 . 
STOPREAS6 .267 1067.216 .000 1 1.000 1.306 .000 . 
Constant 24.416 6638.556 .000 1 .997 .000   
Step 6f NEW_COTE 1.717 .229 56.389 1 .000 5.568 3.557 8.716 
NEW_INITI 1.634 .455 12.892 1 .000 5.123 2.100 12.497 
NEW_MOV
E 
-.931 .204 20.771 1 .000 .394 .264 .588 
NEW_MDR 20.323 8944.183 .000 1 .998 .000 .000 . 
DIS_SITE   13.298 2 .001    
DIS_SITE (1) -.644 .177 13.292 1 .000 .525 .372 .743 
DIS_SITE (2) -.247 .187 1.746 1 .186 .781 .541 1.127 
STOPREAS   .000 6 1.000    
STOPREAS1 .044 2087.786 .000 1 1.000 1.045 .000 . 
STOPREAS2 22.971 6643.721 .000 1 .997 9463.451 .000 . 
STOPREAS3 1.515 7066.220 .000 1 1.000 4.550 .000 . 
STOPREAS4 -.031 8702.609 .000 1 1.000 .969 .000 . 
STOPREAS5 -.091 14925.73
1 
.000 1 1.000 .913 .000 . 
STOPREAS6 .258 1060.316 .000 1 1.000 1.294 .000 . 
Constant 24.206 6643.721 .000 1 .997 .000   
Step 
7g 
NEW_COTE 1.715 .230 55.542 1 .000 5.556 3.539 8.723 
NEW_SITEP 22.357 2630.410 .000 1 .999 .000 .000 . 
NEW_INITI 1.641 .455 13.012 1 .000 5.160 2.116 12.585 
NEW_MOV
E 
-.936 .204 20.981 1 .000 .392 .263 .585 
NEW_MDR 20.327 8942.794 .000 1 .998 .000 .000 . 
DIS_SITE   12.850 2 .002    
DIS_SITE (1) -.635 .177 12.850 1 .000 .530 .375 .750 
DIS_SITE (2) -.231 .188 1.507 1 .220 .794 .549 1.148 
STOPREAS   .000 6 1.000    
STOPREAS1 .049 2087.986 .000 1 1.000 1.051 .000 . 
STOPREAS2 22.975 6646.535 .000 1 .997 9507.483 .000 . 
STOPREAS3 1.514 7068.932 .000 1 1.000 4.543 .000 . 
STOPREAS4 -.031 8705.688 .000 1 1.000 .969 .000 . 
STOPREAS5 -.088 1492.627 .000 1 1.000 .916 .000 . 
STOPREAS6 .258 1063.151 .000 1 1.000 1.294 .000 . 
Constant 24.215 6646.535 .000 1 .997 .000   
 NEW_COTE 1.643 .233 49.765 1 .000 5.173 3.277 8.166 
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NEW_SITEP 22.394 2642.709 .000 1 .999 .000 .000 . 
NEW_INITI 1.671 .455 13.474 1 .000 5.318 2.179 12.979 
NEW_MOV
E 
-.946 .205 21.291 1 .000 .388 .260 .580 
NEW_MDR 20.358 8946.718 .000 1 .998 .000 .000 . 
DIS_SITE   13.963 2 .001    
DIS_SITE (1) -.663 .177 13.963 1 .000 .515 .364 .730 
DIS_SITE (2) -.246 .189 1.688 1 .194 .782 .540 1.133 
STOPREAS   .000 6 1.000    
STOPREAS .178 2093.494 .000 1 1.000 1.195 .000 . 
STOPREAS2 22.984 6620.985 .000 1 .997 9588.297 .000 . 
STOPREAS3 1.471 7044.514 .000 1 1.000 4.353 .000 . 
STOPREAS4 -.039 8683.334 .000 1 1.000 .962 .000 . 
STOPREAS5 -.120 1492.727 .000 1 1.000 .887 .000 . 
STOPREAS6 .273 1062.999 .000 1 1.000 1.313 .000 . 
Constant 24.142 6620.985 .000 1 .997 .000   
Note: Variable(s) entered on step 1: STOPREAS. 
Note: Variable(s) entered on step 2: NEW_COTELIG. 
Note: Variable(s) entered on step 3: NEW_MOVED. 
Note: Variable(s) entered on step 4: NEW_INITINH. 
Note: Variable(s) entered on step 5: DIS_SITE. 
 Note: Variable(s) entered on step 6: NEW_MDR. 
Note: Variable(s) entered on step 7: NEW_SITEPLR. 
 Note: Variable(s) entered on step 8: NEW_PREVTB. 
 
Research Question 1 
What is the relationship between and individual’s ethnic/racial group membership among 
U.S.-born non-Hispanics with an HIVTB co-infection and the likelihood of completion of 
therapy? Tables 14-26 set the framework to determine the impact in answering the research 
question. Upon analysis descriptive outcomes provided the data, power, and variables that 
formed the foundation to determine which specific variables were correlated to both outcomes’ 
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completion of therapy and the reason therapy stopped. Tables 25 and 26 describe all key 
variables as they relate to both dependent variables which suggest that ethnic/racial group 
membership of U.S.-born non-Hispanic co-infected persons is not strongly correlated with either 
completion of therapy or the reasons therapy stopped.  Based on the described outcomes, 
acceptance of the null-hypothesis is required because analysis suggest there is no association 
between race/ethnicity and completion of therapy for persons with co-infection in the United 
States. 
 
Table 27 describes the frequency accuracy of the predictive value of the model in 
systematically predicting outcomes for completion of therapy (n=1,808), (82.5%) and does not 
complete therapy (n=384), (17.5%). 
Table 27 
Dependent Variable Stop Reason (STOPREAS) SPSS (Enter) 
Classification Table 
 
                                                                                
Observed                                      NEW COT           Predicted                 Correct        Percentage 
 
Step 0                                                 0                             0                          681                 0 
                       
                                       1                             0                          384                 0 
Overall Percentage                                                                                       1,808             100 
Note: Constant is included in the model. The cut value is .500 
 
 
Table 28 displays all variables not included in the final logistic regression equation. Each 
variable may be significant on its own in terms of completion of therapy and is noted with a p-
value (<.005) but were not used to identify correlations with dependent variables.  
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Table 28 
 
Variables not in the Equation 
 Score df Sig. 
Step 0 Variables NEW_IDU 7.762 1 .005 
NEW_COTELIG 894.295 1 .000 
NEW_PREVTB 3.998 1 .046 
NEW_SITEPULM .418 1 .518 
NEW_SITEPLR .425 1 .514 
NEW_TBTEST 33.553 1 .000 
NEW_OCCUPATN 22.396 1 .000 
NEW_INITINH 2.885 1 .089 
NEW_INITPZA 14.023 1 .000 
NEW_MOVED .452 1 .502 
NEW_STOPDIED 310.396 1 .000 
NEW_MDR 10.288 1 .001 
NEW_FIRSTLINE .133 1 .715 
RACEHISP 8.249 6 .220 
RACEHISP (1) .938 1 .333 
RACEHISP (2) .851 1 .356 
RACEHISP (3) 4.025 1 .045 
RACEHISP (4) 4.853 1 .028 
RACEHISP (5) .138 1 .710 
RACEHISP (6) .594 1 .441 
ETHNIC (1) 4.853 1 .028 
OCCUPATN 28.158 4 .000 
OCCUPATN (1) 2.134 1 .144 
OCCUPATN (2) .212 1 .645 
OCCUPATN (3) 5.046 1 .025 
OCCUPATN (4) 22.396 1 .000 
PROVTYPE 121.465 4 .000 
PROVTYPE (1) 3.457 1 .063 
PROVTYPE (2) .193 1 .660 
PROVTYPE (3) 95.761 1 .000 
PROVTYPE (4) 104.304 1 .000 
DOTSITE 21.766 4 .000 
DOTSITE (1) .071 1 .790 
DOTSITE (2) .527 1 .468 
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 (table continued) 
DOTSITE (3) 16.246 1 .000 
DOTSITE (4) 4.406 1 .036 
DIS_SITE .501 2 .778 
DIS_SITE (1) .327 1 .567 
DIS_SITE (2) .275 1 .600 
AGE3 26.340 5 .000 
AGE3(1) .638 1 .424 
AGE3(2) 3.025 1 .082 
AGE3(3) 12.035 1 .001 
AGE3(4) .638 1 .424 
AGE3(5) 8.935 1 .003 
NEW_COT 1032.977 1 .000 
DOT 118.135 4 .000 
DOT (1) 5.854 1 .016 
DOT (2) 40.743 1 .000 
DOT (3) .425 1 .515 
DOT (4) 74.158 1 .000 
Note: Residual Chi-Squares are not computed because of redundancies. 
 
 
Table 29 describes the omnibus test for model fit to determine the significance of model 
improvement from the null-model prediction. Statistical significance p-value (<.001), chi-square 




Omnibus Tests of Model Coefficients 
 Chi-square df Sig. 
Step 1 Step 1452.004 42 .000 
Block 1452.004 42 .000 
Model 1452.004 42 .000 





             
Table 30 describes the pseudo R-square Nagelkerke test which describes the proportion 
of variance in the predictor variables (.801) or 81 percent of the variance in the dependent 




Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 582.213a .484 .801 
Note: Estimation terminated at iteration number 20 because maximum iterations have been 
reached. Final solution cannot be found. 
 
Table 31 describes the Hosmer and Lemeshow goodness of fit chi-square=8.000, df=8, 
and p-value=.434 which is greater than p-value=.005 and is conformation that model was 
improved by variables selected for the model and is a goodness of fit. 
Table 31 
 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 8.000 8 .434 
Note: Goodness of fit metric, p-value must be (>.005). 
 
Table 32 describes the logistic regression stepwise contingency table for the Hosmer and 
Lemeshow test for steps 1 through 10 improving the predictive ability of the model to the 








             
Table 32 
 
Contingency Table for Hosmer and Lemeshow Test 
 
NEW_STOPREAS = 0 NEW_STOPREAS = 1 
Total Observed Expected Observed Expected 
Step 1 1 214 206.948 5 12.052 219 
2 116 128.302 103 90.698 219 
3 53 48.054 166 170.946 219 
4 1 .696 215 215.304 216 
5 0 .000 220 220.000 220 
6 0 .000 207 207.000 207 
7 0 .000 217 217.000 217 
8 0 .000 217 217.000 217 
9 0 .000 218 218.000 218 
10 0 .000 240 240.000 240 
Note: Stepwise contingency table predicted outcomes of final regression model.  
 
Table 33 describes the completion of therapy in terms for reasons therapy was stopped in 
12 months classification table which determines the predictive ability of the regression model to 
accurately predict dichotomous outcomes of the dependent variable overall 93.2 percent 





                                                                                
Observed                          NEW STOPREAS           Predicted                 Correct        Percentage 
 
Step 0                                                 0                             302                      82                78.6 
                       
                                       1                             66                        1,742            96.3 
Overall Percentage                                                                                                             93.2 
Note: Constant is included in the model. The cut value is .500 
 
In Table 33, a binomial logistic regression (Enter) analysis was performed on the 
STOPREAS variable to ascertain the effects of: NEW_IDU, NEW_COTELIG, NEW_PREVTB, 
NEW_SITEPULM, NEW_SITEPLR, NEW_TBTEST, NEW_OCCUPATN, NEW_INITINH, 
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NEW_INITPZA, NEW_MOVED, NEW_STOPDIED, NEW_MDR, NEW_FIRSTLINE, 
RACEHISP, STOPREAS, OCCUPATN, PROVTYPE, DOT, DOTSITE, DIS_SITE,  and AGE3 
on the likelihood that cases complete therapy.  
Chi-Square = 1454.091, df =42, p<.0005. The model explained 80.2 percent (Nagelkerke 
R square) of the variance in COT and correctly classified 93.6 percent of cases.  Sensitivity was 
80.7 percent and specificity 96.3 percent. Of the twenty-one predictor variables only three were 
statistically significant: COTELIG, INITPZA, and DIS-SITE 1 (as shown in Table 16). Cases 
that were COTELIG were 11.4 times more likely to complete therapy within 12 months. Cases 
that took PZA as a part of the initial treatment regimen for at least two weeks increased their 
odds of COT by 4.3 times. Cases having pulmonary and plural TB (DIS_SITE 1) decreases their 
likelihood of COT increased odds 3.9 times.  Variables NEW_MDR and New_ FIRSTLINE 
statistical significance were (.051, .057) respectively and are record as marginally significant. 
Both variable, if considered significant would increase odds of COT: NEW_MDR by 5.2 times 
and NEW_FIRSTLINE by 2.1 times.  
Research Question 1 
What is the relationship between and individual’s ethnic/racial group membership among 
U.S.-born non-Hispanics with an HIVTB co-infection and the likelihood of completion of 
therapy? Based on analysis, the null hypothesis is accepted because no demographic variables 
were retained in the final model to include ethnicity/race, gender, and age which are key first 
level independent variables. Alternatively, the completion of therapy eligibility and several 




             
Table 34 
 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 





NEW_IDU -.018 .324 .003 1 .955 .982 .520 1.854 
NEW_COTELI 2.436 .256 90.66 1 .000 11.422 6.918 18.858 
NEW_PREVT .143 .368 .151 1 .698 1.154 .561 2.371 
NEW_SITEPU -.110 1.256 .008 1 .930 .896 .076 10.503 
NEW_SITEPL 19.974 26.473 .000 1 .999 47.00 .000 . 
NEW_TBTEST .452 .246 3.382 1 .066 1.572 .971 2.544 
NEW_OCCUP -.328 .563 .339 1 .560 .720 .239 2.172 
NEW_INITINH -.317 .784 .163 1 .686 .728 .157 3.385 
NEW_INITPZ 1.479 .541 7.472 1 .006 4.387 1.520 12.663 
NEW_MOVED -.259 .317 .668 1 .414 .772 .415 1.436 
NEW_STOPDI 19.902 4. .000 1 .997 .000 .000 . 
NEW_MDR 1.664 .853 3.801 1 .051 5.278 .991 28.107 
NEW_FIRSTLI .775 .407 3.625 1 .057 2.171 .977 4.822 
RACEHISP   2.546 6 .863    
RACEHISP (1) 1.680 1.326 1.605 1 .205 5.363 .399 72.090 
RACEHISP (2) -9.459 188.395 .000 1 1.000 .000 .000 . 
RACEHISP (3) .279 .326 .734 1 .391 1.322 .698 2.505 
RACEHISP (4) .027 .400 .004 1 .947 1.027 .469 2.248 
RACEHISP (5) .458 1.488 .095 1 .758 1.580 .085 29.224 
RACEHISP (6) 16.376 894.362 .000 1 .985 .000 .000 . 
OCCUPATN   1.800 3 .615    
OCCUPAT (1) 20.064 102.445 .000 1 .998 51791 .000 . 
OCCUPAT (2) -9.936 402.849 .000 1 1.000 .000 .000 . 
OCCUPAT (3) 1.194 .890 1.800 1 .180 3.300 .577 18.882 
PROVTYPE   6.618 4 .158    
PROVTYPE (1) -2.193 2.003 1.200 1 .273 .112 .002 5.650 
PROVTYPE (2) -1.480 1.911 .600 1 .439 .228 .005 9.641 
 
         
PROVTYPE (3) -1.655 1.895 .763 1 .382 .191 .005 7.838 
PROVTYPE (4) -2.168 1.897 1.307 1 .253 .114 .003 4.708 
DOTSITE   3.845 4 .427    
DOTSITE (1) 16.874 1213.911 .000 1 .999 .000 .000 . 
DOTSITE (2) 18.142 1213.911 .000 1 .999 .000 .000 . 
DOTSITE (3) 17.933 1213.911 .000 1 .999 .000 .000 . 
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DIS_SITE   19.81 2 .000    
DIS_SITE (1) 1.379 .311 19.85 1 .000 3.971 2.159 7.303 
DIS_SITE (2) 1.069 1.284 .693 1 .405 2.912 .235 36.072 
AGE3   2.440 5 .785    
AGE3(1) 10.015 2316.747 .000 1 1.000 .000 .000 . 
AGE3(2) .642 .968 .440 1 .507 1.901 .285 12.682 
AGE3(3) .545 .686 .631 1 .427 1.724 .450 6.612 
AGE3(4) 21.158 215.004 .000 1 .999 1537.292 .000 . 
AGE3(5) .235 .681 .119 1 .730 1.265 .333 4.804 
NEW_COT 30.845 1164.928 .001 1 .979 242.490 .000 . 
DOT   23.45 4 .000    
DOT (1) 16.135 1281.681 .000 1 .990 101.676 .000 . 
DOT (2) 18.857 1281.680 .000 1 .988 1547740 .000 . 
DOT (3) 18.056 1281.680 .000 1 .989 694.580 .000 . 
DOT (4) 16.766 1281.680 .000 1 .990 1911858 .000 . 
Constant -3.078 12191.45 .000 1 1.000 .046   
Note: Variable(s) entered on step 1: NEW_IDU, NEW_COTELIG, NEW_PREVTB, 
NEW_SITEPULM, NEW_SITEPLR, NEW_TBTEST, NEW_OCCUPATN, NEW_INITINH, 
NEW_INITPZA, NEW_MOVED, NEW_STOPDIED, NEW_MDR, NEW_FIRSTLINE, 
RACEHISP, OCCUPATN, PROVTYPE, DOTSITE, DIS_SITE, AGE3, NEW_COT, DOT. 
 
Table 34 
Dependent Variable Stop Reason SPSS (Forward LR) 
Classification Table 
 
                                                                                
Observed                             NEW _STOPREAS       Predicted                Correct        Percentage 
 
Step 0                                                 0                             0                          484                 0 
                       
                                       1                             0                          1,808             100.0 
Overall Percentage                                                                                                              82.5 




             
Table 35 displays all variables not included in the final logistic regression equation. Each 
variable may be significant on its own in terms of completion of therapy and is noted with a p-
value (<.005) but were not used to identify correlations with dependent variables.  
Table 35 
 
Variables not in the Equation 
 Score df Sig. 
 
Step 0 
Variables NEW_IDU 7.762 1 .005 
NEW_COTELIG 894.295 1 .000 
NEW_PREVTB 3.998 1 .046 
NEW_SITEPULM .418 1 .518 
NEW_SITEPLR .425 1 .514 
NEW_TBTEST 33.553 1 .000 
NEW_OCCUPATN 22.396 1 .000 
NEW_INITINH 2.885 1 .089 
NEW_INITPZA 14.023 1 .000 
NEW_MOVED .452 1 .502 
NEW_STOPDIED 310.396 1 .000 
NEW_MDR 10.288 1 .001 
NEW_FIRSTLINE .133 1 .715 
RACEHISP 8.249 6 .220 
RACEHISP (1) .938 1 .333 
   
RACEHISP (2) .851 1 .356 
RACEHISP (3) 4.025 1 .045 
RACEHISP (4) 4.853 1 .028 
RACEHISP (5) .138 1 .710 
RACEHISP (6) .594 1 .441 
ETHNIC (1) 4.853 1 .028 
OCCUPATN 28.158 4 .000 
OCCUPATN (1) 2.134 1 .144 
OCCUPATN (2) .212 1 .645 
OCCUPATN (3) 5.046 1 .025 
OCCUPATN (4) 22.396 1 .000 
PROVTYPE 121.465 4 .000 
PROVTYPE (1) 3.457 1 .063 
PROVTYPE (2) .193 1 .660 
PROVTYPE (3) 95.761 1 .000 
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           (table continued) 
    
PROVTYPE (4) 104.304 1 .000 
DOTSITE 21.766 4 .000 
DOTSITE (1) .071 1 .790 
DOTSITE (2) .527 1 .468 
DOTSITE (3) 16.246 1 .000 
DOTSITE (4) 4.406 1 .036 
DIS_SITE .501 2 .778 
DIS_SITE (1) .327 1 .567 
DIS_SITE (2) .275 1 .600 
AGE3 26.340 5 .000 
AGE3(1) .638 1 .424 
AGE3(2) 3.025 1 .082 
AGE3(3) 12.035 1 .001 
AGE3(4) .638 1 .424 
AGE3(5) 8.935 1 .003 
NEW_COT 1032.977 1 .000 
DOT 118.135 4 .000 
DOT (1) 5.854 1 .016 
DOT (2) 40.743 1 .000 
DOT (3) .425 1 .515 
DOT (4) 74.158 1 .000 
Note: Residual Chi-Squares are not computed because of redundancies. 
 
Table 36 describes the pseudo R-square Nagelkerke test which describes the proportion 
of variance in the predictor variables (.788) or 78.8 percent of the variance in the dependent 








             
Table 36 
Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 932.921a .395 .653 
2 762.818a .440 .728 
3 721.497a .451 .745 
4 683.392a .460 .761 
5 665.330a .464 .768 
6 642.050a .470 .777 
7 627.391a .474 .783 
8 619.958a .475 .786 
9 615.807a .476 .788 
Note: Estimation terminated at iteration number 20 because maximum iterations have been 
reached. Final solution cannot be found. 
 
Table 37 describes the logistic regression stepwise contingency table for the Hosmer and 
Lemeshow test for steps 1 through 9 improving the predictive ability of the model to the 
expected values in the final model.  
Table 37 
Hosmer and Lemeshow Test 
Step Chi-square df Sig. 
1 .000 0 . 
2 .000 2 1.000 
3 22.371 5 .000 
4 16.358 6 .012 
5 15.803 6 .015 
6 22.536 6 .001 
7 20.676 7 .004 
8 16.300 7 .023 
9 12.454 7 .087 




             
Table 38 describes the logistic regression stepwise contingency table for the Hosmer and 
Lemeshow test for steps 1 through 9 improving the predictive ability of the model to the 
expected values in the final model.  
Table 38 
 
Contingency Table for Hosmer and Lemeshow Test 
 
NEW_STOPREAS = 0 NEW_STOPREAS = 1 
Total Observed Expected Observed Expected 
Step 1 1 384 384.000 297 297.000 681 
2 0 .000 1511 1511.000 1511 
Step 2 1 273 273.000 65 65.000 338 
2 111 111.000 232 232.000 343 
3 0 .000 55 55.000 55 
4 0 .000 1456 1456.000 1456 
Step 3 1 175 163.264 8 19.736 183 
2 98 109.736 57 45.264 155 
3 79 90.736 143 131.264 222 
4 32 20.264 144 155.736 176 
5 0 .000 1044 1044.000 1044 
6 0 .000 222 222.000 222 
7 0 .000 190 190.000 190 
Step 4 1 199 188.374 11 21.626 210 
2 90 102.008 65 52.992 155 
3 71 78.318 137 129.682 208 
4 24 15.299 203 211.701 227 
5 0 .000 689 689.000 689 
6 0 .000 333 333.000 333 
7 0 .000 259 259.000 259 
8 0 .000 111 111.000 111 
Step 5 1 220 212.117 19 26.883 239 
2 112 133.385 136 114.615 248 
3 52 38.498 161 174.502 213 
4 0 .000 92 92.000 92 
5 0 .000 647 647.000 647 
6 0 .000 318 318.000 318 
7 0 .000 247 247.000 247 
8 0 .000 188 188.000 188 
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(table continued) 


















2 126 149.421 149 125.579 275 
3 51 39.952 164 175.048 215 
4 0 .000 90 90.000 90 
5 0 .000 647 647.000 647 
6 0 .000 320 320.000 320 
7 0 .000 247 247.000 247 
8 0 .000 188 188.000 188 
Step 7 1 214 202.600 4 15.400 218 
2 87 104.221 80 62.779 167 
3 67 67.334 143 142.666 210 
4 16 9.845 209 215.155 225 
5 0 .000 109 109.000 109 
6 0 .000 576 576.000 576 
7 0 .000 291 291.000 291 
8 0 .000 228 228.000 228 
9 0 .000 168 168.000 168 
Step 8 1 212 202.566 5 14.434 217 
2 92 108.380 83 66.620 175 
3 67 64.971 144 146.029 211 
4 13 8.083 215 219.917 228 
5 0 .000 115 115.000 115 
6 0 .000 564 564.000 564 
7 0 .000 298 298.000 298 
8 0 .000 219 219.000 219 
9 0 .000 165 165.000 165 
      
       
      
      
      





             
Table 39 describes the reason therapy was stopped classification table which determines 
the predictive ability of the regression model to accurately predict dichotomous outcomes of the 










 0 1  
Step 1 NEW_STOPREAS 0 384 0 100.0 
1 297 1511 83.6 
Overall Percentage   86.5 
Step 2 NEW_STOPREAS 0 273 111 71.1 
1 65 1743 96.4 
Overall Percentage   92.0 
Step 3 NEW_STOPREAS 0 273 111 71.1 
1 65 1743 96.4 
Overall Percentage   92.0 
Step 4 NEW_STOPREAS 0 283 101 73.7 
1 64 1744 96.5 
Overall Percentage 
 













Step 5 NEW_STOPREAS 0 276 108 71.9 
1 60 1748 96.7 
Overall Percentage   92.3 
Step 6 NEW_STOPREAS 0 278 106 72.4 
1 60 1748 96.7 
Overall Percentage   92.4 
Step 7 NEW_STOPREAS 0 293 91 76.3 
1 73 1735 96.0 
Overall Percentage   92.5 
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Step 8 NEW_STOPREAS 0 294 90 76.6 
 
1 74 1734 95.9 
Overall Percentage   92.5 
Step 9 NEW_STOPREAS 0 292 92 76.0 
1 71 1737 96.1 
Overall Percentage   92.6 
Note: The cut value is .500 
 
Research Question 2  
 Is there a relationship/association for completing therapy among TB/HIV co-infected 
U.S.-born non-Hispanics with an HIV/TB co-infection moderated by completion of therapy 
eligibility? Based on the analysis, the null hypothesis is rejected because completion of eligibility 
and clinical variables were retained in the final model which indicated correlations and well as 
strong associations to reason therapy was stopped.  Analysis show a relationship/association for 
completing therapy among TB/HIV co-infected U.S.-born non-Hispanics with an HIV/TB co-
infection moderated by completion of therapy eligibility. The alternative hypothesis is accepted.   
 
Table 40 describes all variables retained in the equation and are evaluated in the analysis 
one variable at a time while controlling for other variables in the model to determine the final 
model configuration. A binomial logistic regression (Forward LR) analysis was performed on the 
STOPREAS variable to ascertain the effects of: NEW_IDU, NEW_COTELIG, NEW_PREVTB, 
NEW_SITEPULM, NEW_SITEPLR, NEW_TBTEST, NEW_OCCUPATN, NEW_INITINH, 
NEW_INITPZA, NEW_MOVED, NEW_STOPDIED, NEW_MDR, NEW_FIRSTLINE, 
RACEHISP, STOPREAS, OCCUPATN, PROVTYPE, DOT, DOTSITE, DIS_SITE, and AGE3 
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on the likelihood that cases complete therapy. Chi-Square = 1422.419, df =14, p<0.0005. The 
model explained 79.0 percent (Nagelkerke R square) of the variance in COT and correctly 
classified 93.6 percent of cases.  Sensitivity was 77.3 percent and specificity were 96.6 percent. 
Of the twenty-one predictor variables only six were statistically significant: NEW_COTELIG, 
NEW_INITPZA, NEW_MDR, NEW_FIRSTLINE, DIS_SITE 1, AND DIS_SITE 2, (as shown 
in Table 16). Cases that were COTELIG were 11.6 times more likely to complete therapy within 
12 months. Cases that took PZA as a part of the initial treatment regimen for at least two weeks 
decreased their odds of COT by 3.4 times. Cases that were resistant to first line TB drugs were 
3.5 times more likely to complete therapy. Cases with DIS_SITE 1 (extra pulmonary only) were 
3.6 times more likely to complete therapy Cases with DIS_SITE 2 (both pulmonary and extra 
pulmonary) were 3.2 times more likely to complete therapy.  Cases diagnosed with MDR TB 
increased were 12.2 times more likely to complete therapy period.  
Additional Statistical Significance 
Other predictor variables with strong association were (previous TB and moved) were 
both negatively associated to completion of therapy and the reason therapy stopped. Analysis 
suggest that cases were at higher odds for not completing treatment if they were a previous case, 
have moved during treatment, or were not eligible to complete treatment. In contrast, variables 
for the initiation of TB drugs (INH, and PZA), MDR TB, and site of disease 1 were all positively 
associated with increasing the odds of completing treatment. 
 In the overall model, six statistically significant predictor variables (PREVTB, INITINH, 
INITPZA, MDR, DIS_SITE 1, and COTELIG) have strong positive and negative associations to 
completion of treatment either within 12 months or at any time. Based on logistic regression 
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analysis, the null hypothesis was rejected. There are six NTSS variables that provide the most 
significant odds ratios associated with completion within 12 months or at any other time during 
treatment.   
Each research question was addressed in these analyses. Clinical, demographic, and 
outcome variables have shown both positive and negative associations to the completion of 
therapy for this TB/HIV co-infected population. Variables that were not used in the equation 
provided evidence that some predictors are statistically significant as a single variable. If 
associated variables were added alone into the equation, each would have an independent 
association to both dependent variables but were excluded based on overall significance from the 
final logistic regression model.  Statistical significance was noted among individual independent 
variables not used in the equation. Analysis did show a significant p-value associated with the 
dependent variable completion of therapy within 12 months. Completion of treatment is 
influenced by several demographic, clinical, and outcome variables described in the NTSS 
dataset. Most importantly of the individual variables to note is a significance among non-
Hispanic Blacks p-value = .000, score = 6.586, df = 1 suggests that being Black has an 
association with completion of treatment or not completing treatment which require further 
investigation. The association also suggests that non-Hispanic Blacks have some level of 
disparity described in the literature review section that may require specific public health 
interventions.   
Analysis of the dependent variable reason therapy was stopped when applied to the 
model showed statistical similar associations noted among variables not in the equations as well. 
Findings identified several demographics, clinical, and outcome independent variables with 
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association when applied to the completion of treatment at any time the reason therapy stopped   
dependent variable was individually significant. Two statistically significantly variables for 
race/ethnicity were observed. Non-Hispanic Blacks and Hispanics as a race were statistically 
significant as individual predictors only and are not included in the final model. Non-Hispanic 
Blacks p-value = .045, score = 4.025, df = 1 and Hispanics as a race p-value = .028, score = 
4.853, df = 1.  
The output suggests that both variables are associated to completion of treatment at any 
time and they both require further investigation to determine if there are negatively or positively 
correlated to completing treatment at any time. In addition, two demographics for age categories 
were identified as significant among variables not in the equation. Age3 groups (15-24 years and 
65+ years) were significant p-value = .001, score = 12.035, df = 1 and p-value = .003, score = 
8.935, df = 1 respectively. Both outcomes suggest that both age categories have an association to 
the reason therapy stopped as individual predictors only and are not included in the final model. 
Table 40 
Variables in the Equation 
 B S.E. Wald df Sig. Exp(B) 





NEW_COT 21.460 103.994 .000 1 .983 20.196 .000 . 
Constant -.257 .077 11.054 1 .001 .773   
Step 
2b 
NEW_COTELI 2.172 .180 14.792 1 .000 8.778 6.170 12.490 
NEW_COT 20.682 101.877 .000 1 .984 9591.782 .000 . 
Constant -1.435 .138 108.12
2 




NEW_COTELI 2.482 .203 14.639 1 .000 11.967 8.040 17.811 
DIS_SITE   37.143 2 .000    
DIS_SITE (1) 1.349 .258 27.390 1 .000 3.853 2.325 6.386 
DIS_SITE (2) 1.133 .241 22.087 1 .000 3.105 1.936 4.981 
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  (table continued) 
         
NEW_COT 20.695 1011.73
8 
.000 1 .984 9725017
98.681 
.000 . 
Constant -2.113 .193 119.45
5 




NEW_COTELI 2.416 .209 13.034 1 .000 11.199 7.428 16.883 
DIS_SITE   33.588 2 .000    
DIS_SITE (1) 1.354 .268 25.443 1 .000 3.872 2.288 6.553 
DIS_SITE (2) 1.090 .249 19.207 1 .000 2.974 1.827 4.843 
NEW_COT 27.832 118.760 .001 1 .981 122.888 .000 . 
DOT   29.786 4 .000    
DOT (1) 12.745 841.246 .000 1 .988 3428.266 .000 . 
DOT (2) 15.424 841.245 .000 1 .985 4993.562 .000 . 
DOT (3) 14.654 841.245 .000 1 .986 2311837.
233 
.000 . 
DOT (4) 13.494 841.245 .000 1 .987 7252.549 .000 . 
Constant 16.776 841.245 .000 1 .984 .000   
Step 
5e 
NEW_COTELI 2.588 .221 13.917 1 .000 13.302 8.623 20.520 
NEW_FIRSTLI 1.428 .343 17.331 1 .000 4.172 2.130 8.174 
DIS_SITE   31.675 2 .000    
DIS_SITE (1) 1.292 .273 22.448 1 .000 3.640 2.133 6.213 
DIS_SITE (2) 1.126 .255 19.467 1 .000 3.084 1.870 5.087 
NEW_COT 26.355 113.549 .000 1 .982 2798.385 .000 . 
DOT   29.074 4 .000    
DOT (1) 12.555 837.905 .000 1 .988 2832.093 .000 . 
DOT (2) 15.300 837.904 .000 1 .985 4410.356 .000 . 
DOT (3) 14.564 837.904 .000 1 .986 2118.572 .000 . 
DOT (4) 13.376 837.904 .000 1 .987 6442.148 .000 . 
Constant 16.906 837.904 .000 1 .984 .000   
Step 6f NEW_COTELI 2.378 .226 11.676 1 .000 10.779 6.922 16.787 
NEW_STOPDI 19.779 476.312 .000 1 .997 .000 .000 . 
NEW_FIRSTLI 1.384 .353 15.351 1 .000 3.990 1.997 7.972 
DIS_SITE   29.289 2 .000    
DIS_SITE (1) 1.262 .278 20.644 1 .000 3.532 2.049 6.086 
DIS_SITE (2) 1.105 .259 18.183 1 .000 3.019 1.817 5.017 
NEW_COT 26.444 1188.16
4 




DOT   26.032 4 .000    
DOT (1) 12.576 841.023 .000 1 .988 2897.266 .000 . 
DOT (2) 15.277 841.023 .000 1 .986 4314.806 .000 . 
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DOT (3) 14.649 841.023 .000 1 .986 2311.834 .000 . 
DOT (4) 13.443 841.023 .000 1 .987 6894.229 .000 . 
Constant -
16.733 




NEW_COTELI 2.348 .228 10.645 1 .000 10.465 6.688 16.375 
NEW_OCCUP
ATN 
-1.102 .298 13.645 1 .000 .332 .185 .596 
NEW_STOPDI 19.927 478.925 .000 1 .997 .000 .000 . 
NEW_FIRSTLI 1.284 .357 12.972 1 .000 3.613 1.796 7.268 
DIS_SITE   24.976 2 .000    
DIS_SITE (1) 1.188 .280 17.952 1 .000 3.282 1.894 5.686 
DIS_SITE (2) 1.021 .262 15.224 1 .000 2.776 1.662 4.637 
NEW_COT 26.520 112.825 .001 1 .982 32987 .000 . 
DOT   25.182 4 .000    
DOT (1) 12.616 837.175 .000 1 .988 3015.049 .000 . 
DOT (2) 15.435 837.174 .000 1 .985 5056.099 .000 . 
DOT (3) 14.820 837.174 .000 1 .986 2799.908 .000 . 
DOT (4) 13.628 837.174 .000 1 .987 8293.887 .000 . 
Constant -
16.689 




NEW_COTELI 2.395 .233 10.980 1 .000 10.971 6.953 17.310 
NEW_OCCUP -1.145 .302 14.403 1 .000 .318 .176 .575 
NEW_INITPZ 1.192 .446 7.152 1 .007 3.295 1.375 7.895 
NEW_STOPDI 19.989 470.592 .000 1 .997 .000 .000 . 
NEW_FIRSTLI 1.275 .360 12.570 1 .000 3.579 1.769 7.242 
DIS_SITE   27.015 2 .000    
DIS_SITE (1) 1.235 .284 18.952 1 .000 3.438 1.972 5.994 
DIS_SITE (2) 1.108 .266 17.323 1 .000 3.030 1.798 5.106 
NEW_COT 26.519 11.364 .001 1 .982 328.814 .000 . 
DOT   25.250 4 .000    
DOT (1) 12.741 835.409 .000 1 .988 341.073 .000 . 
DOT (2) 15.489 835.408 .000 1 .985 5325.445 .000 . 
DOT (3) 14.880 835.408 .000 1 .986 2891.294 .000 . 
DOT (4) 13.647 835.408 .000 1 .987 8445.814 .000 . 
Constant 17.923 835.408 .000 1 .983 .000   
Step 9i NEW_COTELI 2.456 .237 107.62 1 .000 11.654 7.328 18.533 
NEW_OCCUP -1.143 .303 14.231 1 .000 .319 .176 .578 
NEW_INITPZ 1.212 .445 7.405 1 .007 3.361 1.404 8.048 
NEW_STOPDI 20.028 473.096 .000 1 .997 .000 .000 . 
NEW_MDR 1.607 .810 3.936 1 .047 4.989 1.020 24.408 
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NEW_FIRSTLI .933 .387 5.813 1 .016 2.543 1.191 5.429 
DIS_SITE   28.522 2 .000    
DIS_SITE (1) 1.286 .288 19.996 1 .000 3.619 2.060 6.360 
DIS_SITE (2) 1.170 .270 18.752 1 .000 3.223 1.898 5.475 
NEW_COT 26.851 117.177 .001 1 .982 4584.794 .000 . 
DOT   26.622 4 .000    
DOT (1) 12.634 834.306 .000 1 .988 3015.516 .000 . 
DOT (2) 15.478 834.305 .000 1 .985 5295.543 .000 . 
DOT (3) 14.885 834.305 .000 1 .986 2912.029 .000 . 
DOT (4) 13.540 834.305 .000 1 .987 759.590 .000 . 
Constant 17.997 834.305 .000 1 .983 .000   
Note: Variable(s) entered on step 1: NEW_COT. 
Note: Variable(s) entered on step 2: NEW_COTELIG. 
Note: Variable(s) entered on step 3: DIS_SITE. 
Note: Variable(s) entered on step 4: DOT. 
Note: Variable(s) entered on step 5: NEW_FIRSTLINE. 
Note: Variable(s) entered on step 6: NEW_STOPDIED. 
Note: Variable(s) entered on step 7: NEW_OCCUPATN. 
Note: Variable(s) entered on step 8: NEW_INITPZA. 
Note: Variable(s) entered on step 9: NEW_MDR. 
 
Table 41 outlines the summary of outputs for stepwise forward logistic regression 
statistically significant variables that were strongly correlated with reason therapy was stopped. 
Associations to the dependent variable through the analysis of odds ratios and probabilities were 
described to show the likelihood for an individual to complete therapy while controlling for all 







             
Table 41 
Statistically Significant Independent Variables (NEW_STOPREAS enter) 
Significant Variable                                     Odds Ratio                              Probability 
   
NEW_COTELIG,     11.4 times more likely   92% COT  
**NEW_NOTCOTELIG   .094 times less likely    9% COT 
NEW_INITPZA,     4.3 times more likely   81% COT 
DIS_SITE 1,      3.9 times more likely   80% COT 
______________________________________________________________________________ 
Note: **Denotes chance of not completing therapy. 
 
Table 42 outlines the summary of outputs for binomial logistic regression statistically 
significant variables that were strongly correlated to completion of therapy within 12 months. 
Associations to the dependent variable through the analysis of odds ratios and probabilities were 
described to show the likelihood for an individual to complete therapy within 12 months while 




Statistically Significant Independent Variables (NEW_COT enter) 
Significant Variable                                   Odds Ratio                                  Probability 
   
NEW_COTELIG,      5.4 times more likely   84% COT  
*NEW_NOTCOTELIG   .183 times less likely   15% COT 
PREVTB      .544 times less likely   35% COT 
NEW_INITINH,      5.9 times more likely   86% COT 
NEW_MOVED     .425 times less likely   30% COT 
DIS_SITE 1      .451 times less likely   31% COT 
 
Note: *Denotes chances of not completing therapy. 
 
 
Table 43 outlines the summary of outputs for stepwise forward logistic regression 
statistically significant variables that were strongly correlated with reason therapy was stopped. 
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Associations to the dependent variable through the analysis of odds ratios and probabilities were 
described to show the likelihood for an individual to complete therapy while controlling for all 
other variables in the final regression model.  
Table 43 
Statistically Significant Independent Variables (STOPREAS Forward LR) 
Significant Variable                                        Odds Ratio                            Probability 
   
NEW_COTELIG,      11.6 times more likely 92% COT  
*NEW_NOTCOTELIG    .092 times less likely   8% COT 
NEW_INITPZA,      3.4 times more likely  77% COT 
NEW_MDR,       4.9 times more likely  92.4% COT 
NEW_FIRSTLINE,      3.5 times more likely  78% COT 
DIS_SITE 1,       3.6 times more likely  78% COT 
DIS_SITE 2,      3.2 times more likely  76% COT 
 
Note: *Denotes chances of not completing therapy. 
 
Table 44 outlines the summary of outputs for stepwise forward logistic regression 
statistically significant variables that were strongly correlated with completion of therapy within 
12 months. Associations to the dependent variable through the analysis of odds ratios and 
probabilities were described to show the likelihood for an individual to complete therapy while 
controlling for all other variables in the final regression model.  
Table 44 
Statistically Significant Independent Variables (NEW_COT Forward LR) 
Significant Variable                                  Odds Ratio                        Probability 
   
NEW_COTELIG,     5.1 times more likely  83.6% COT  
*NEW_NOTCOTELIG   .084 times less likely  8% COT 
NEW_INITINH    5.3 times more likely  84.1% COT 
NEW_PREVTB,     .578 times less likely             37% COT 
NEW_MOVED,     .388 times less likely  28% COT 
DIS_SITE 1,      .515 times less likely  34% COT 
 




             
                                                           Summary 
 
Research question one asks, what relationship between and individual’s ethnic/racial 
group membership among U.S.-born non-Hispanics with an HIVTB co-infection and the 
likelihood of completion of therapy? Logistic regression identifies no significant associations 
among ethnic/race, age, or gender in the overall model to the completion of therapy within 12 
months or at any time during treatment. No ethnic or racial group was correlated with having a 
significant odds ratio over any other group. The lack of a statistically significance outcome in the 
final model suggests that the null hypothesis should be accepted to state no U.S.-born non-
Hispanic co-infected ethnic/racial groups are more likely to complete therapy within 12 months 
or at any other time during treatment across all races.  
Research question two asks, is there a relationship/association for completing therapy 
among TB/HIV co-infected U.S.-born non-Hispanics with an HIV/TB co-infection moderated by 
completion of therapy eligibility? Logistic regression shows both dependent variables 
completion of therapy and the reason therapy stopped produced association to other several 
predictor variables. Although ethnicity/race, age, and gender were not significant in the overall 
regression model, clinical and other demographic variable were strongly associated with 
completion of treatment.  
Chapter 5 describes a detailed interpretation of findings, study limitations, recommendations, 





             
Chapter 5: Discussion, Conclusions, and Recommendations 
 
Introduction 
This chapter describes statistical significance of 20 key variables with strong correlations 
and direct associations to completion of therapy and the reason therapy stopped. Positive and 
negative associations were recorded as odds ratios for the likelihood of completing therapy 
within 12 months as defined by CDC. The project outlines the stop-reason variable which 
describes seven categorical reasons therapy was stopped and recoded in the data set as a 
dichotomous dependent variable completion of therapy at any time during treatment. A summary 
and interpretation of key findings are discussed which includes individual variable analysis, 
interpretation, and significance of outputs as they relate to eligibility for completion for all cases. 
Positive and negative aspects of each correlated key variable is discussed focusing on strengths 
and limitations of the model and design.  The chapter will conclude with national and local 
recommendations for future initiatives as well as programmatic implications for social change.    
The purpose of this study was to identify and determine key independent variables 
correlated and associated with completion of therapy with a focus on non-Hispanic Blacks in the 
United States. A longitudinal analysis was performed with the NTSS data set Report of Verified 
Cases of TB 2009 thru 2014 for key demographic, clinical, and outcome variables. The nature of 
this study was to use an advanced logistic regression model to help provide the foundation to 
calculate odds ratios to identify ethnic/racial disparity among groups that were at higher or lesser 
odds for completing therapy. In contrast, the overarching secondary intent of the study was to 
describe all statistically significant variables and combinations of variables that correlate to 
positive or negative outcomes for completion of therapy among this high-risk population. The 
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study was conducted to provide a perspective for completion of therapy characteristics that may 
help TB control practitioners describe expected outcomes to patients and staff based on current 
statistics using odds ratios and probabilities outlined in this study. Practitioners can use statistics 
to show meeting programmatic performance measures translates to positive outcomes that 
includes treatment completion.   
                                       Interpretation of Findings 
 The findings of this study are intended to provide data that adds to the emerging co-
infection concerns for public health practitioners to understand TB disease epidemiology and 
variables associated with completion of therapy. Marks et al., (2007) presented a poster at the 
national TB conference that described and acknowledged the problem of managing patients with 
other comorbidities who died before they finished treatment. The poster presentation highlighted 
coinfection complications and the importance of health care partnerships through program 
collaboration and system integration. 
 Currently, public health practitioners investigate the common theme for TB in the US by 
focusing on high-risk foreign-born populations where resources and funding are concentrated. 
Foreign-born persons have a higher risk of developing TB primarily because many countries 
have greater risk-factors, higher rates, and incidence cases. This epidemiology has prompted a 
creative public health initiative for this high-risk population (WHO, 2014b).  As a result, more 
focus has been placed on research and targeted interventions for the foreign-born population in 
the United States (CDC, 2014a).  Colson (2014) began to describe characteristics of U.S.-born 
cases recording differences in attitudes among non-Hispanic Blacks and Whites which provided 
a framework for further investigation. McDonald et al. (2015) were one of the first researchers to 
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use national surveillance data for TB/HIV co-infection in Scotland. Efforts have waned in the 
U.S. based on overall research costs and the struggle to facilitate inter-agency collaborations 
(CDC, 2014a).  
The foundation for my study was based on the gaps in data and co-infection literature that 
focuses on U.S.-born populations. In addition, this study was designed to extend the knowledge 
gained from research performed in Scotland that focused analysis on coinfection and risk-factors 
in completing therapy. Completion of therapy is the expectation result and focus for many TB 
control programs. Understanding those specific variables that contribute to completion of therapy 
is a critical next step for TB control.  
After conducting an exhaustive literature review, my investigation did not find any other 
researchers to implement the TB/HIV coinfection model to access odds ratios for completing 
therapy for U.S.-born cases. Thus, provided the foundation for my project and support for future 
projects focusing on co-morbidities. The final analysis was grounded in the SDOH theoretical 
framework and evidence-based methods that establish conditions through relationships, 
demographics, workplace, and risk factors to evoke change and affect the quality of life (Glanz 
et al., 2008). 
 In the context of SDOH framework, data analysis suggests that ethnicity/race, gender, 
and age were not statistically significant in the logistic regression model as expected from 
reported disparities among racial groups (Magee et al., 2007). All variables considered, each 
individual TB case had the same odd ratio for completing therapy among cases reported in the 
NTSS database. My interpretation of the results is that public health equity for completion of 
therapy is present across all ethnic/racial groups and provides some evidence of programmatic 
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success for progress towards TB elimination. The most significant variables associated with 
COT were clinical and demographic predictors for eligibility to complete therapy, previous 
history of TB, site of disease, initiation of INH within the first two weeks of diagnosis and 
moved at any time during treatment. 
 Non-Hispanic Blacks had twice as many cases of coinfection than non-Hispanic White 
and many more times than other racial and ethnic group. There is an obvious disparity among 
non-Hispanic Blacks, but results provide no evidence of greater or lesser odds ratios for 
completing therapy or completing therapy at any time during treatment. As a parallel analysis, 
the reason therapy stopped was statistical significance for completion of therapy eligibility, 
initiation of pyrazinamide within the first two weeks, pulmonary disease site, multi-drug 
resistance, and start of initial four drug regimen (INH, RIF, PZA, and EMB) to increase the odds 
ratio for completing therapy at any time during treatment.  
The results show a large correlation to the completion of therapy eligibility variable and 
statistical significance for cases who were eligible to complete therapy in 12 months versus those 
cases that were not eligible to complete therapy. The analysis methodology states if all predictor 
variables are held constant, completion of therapy eligibility cases are 11.4 times more likely to 
complete therapy. Data analysis shows no negative odds ratios were associated with the reason 
therapy stopped which suggests with all variables considered, cases are more likely to finish 
therapy at some point during treatment if they have not died, refused therapy, were lost to 
follow-up, experienced an adverse event, or moved. These findings can be interpreted as positive 




             
Limitations of the Study 
The study provided several conditions and situations that limited the generalizability of 
outcomes. The use of secondary analysis brought inherited data misclassification concerns to the 
project. Analysis are based on surveillance data that is aggregated from various reporting units 
around the U.S. Thus, there may be greater variability in data quality and completeness. The 
race/ethnicity variable was the most glaring issue with the NTSS dataset, because the multi-race 
selection was added to the RVCT in 2010 and may not capture all cases from 2009.  
The CDC (2007a) Report of Verified Case of Tuberculosis 2009 may have missing 
records prior to 2009, because reporting was voluntary. Self-reporting of race may not be 
consistent and may vary depending on an individual’s perception about race and ethnicity. 
California did not report HIV status from (2008 – 2010). Based on this condition, California 
cases were deleted from the denominator and the data set was re-evaluated completeness and 
statistical power.   
Data from 2008 and 2009 may not reflect those truly unemployed. A consistent definition 
of current variables including unemployed were not fully implemented until 2010. The COT 
variable may take up to two years for updating, some completion of therapy variables for 2016 
may be incomplete. To account for possible incomplete completion of therapy data points, a 
cross matching technique was performed and was determined to have no missing variables. 
Cases with “unknown” U.S. status were removed from denominator using a trimming statistical 
technique to complete the dataset and was re-evaluated for appropriate statistical power.  
Binomial logistic regression analysis brought some limitation to the study, because the 
technique cannot show causation. The statistical output can only describe predictor variable 
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correlations and Exp. (Beta) as an odds ratio. Inferences and associations are the limitation of 
these analysis. Despite this limitation, validity of outcomes and trustworthiness of results are 
generalizable to the theoretical model and quantitative methods (Creswell, 2009).  
Recommendations 
This study has provided a small platform to continue the future investigation and 
validation of U.S.-born TB/HIV coinfected cases as well foreign-born and other high-risk 
populations. Further research is needed via the multiple regression model for the reason therapy 
stopped dependent variable to understand how completion of therapy correlates to each 
categorical level i.e. (completed, adverse, died, lost, moved, other, and refused).  
In addition, a comprehensive research design focused on comparing means of U.S.-born 
and foreign-born cases with both HIV/TB co-infection and negative HIV status to further 
describe and understand predictor variables associated with completion of therapy and 
completion of therapy at any time during treatment. Each project will help identify if any 
ethnic/racial groups are at risk of not completing therapy and describe the conditions that best 
support positive outcomes through analysis of each correlated predictor variable. Research could 
also be expanded to evaluating the more than 300 RVCT clinical and demographic variables not 
used in my current study to show a comprehensive picture of TB control performance measures 
in the United States.  
Future studies have the potential to provide a longitudinal evaluation of the most 
important metric in national TB elimination model to cure disease and intervene against further 
transmission (CDC, 2014a; WHO, 2014a). Finding of this study as well as future projects may 
contribute to guidelines and policies that support public health initiatives that address disparities 
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noted from proposed analysis. Stakeholders, as well as policy maker, and public health partners 
as suggested to (PCSI) to offset expenses of performing systematic analysis of the NTSS. The 
findings of this study also recommend that merging of databases should be considered long-term 
for all infectious disease programs to address emerging concerns for all co-morbidities that affect 
health and QOL. 
Positive Social Change  
The implications of this study are relevant for the individual, families, organizations and 
society in regards of understanding fundamental TB principles and circumstances that place an 
individual at risk for completing or not completing therapy. Odd ratios are metrics that are easy 
to digest and translatable to persons that are not familiar with medical terms and language. In 
contrast to other medical outcomes that are heavy with scientific jargon, risk factors such as odds 
ratios clarify relationships of positive and negative associations against normal outcomes. 
Having an easier subject matter in TB education design, may help practitioners translate to a 
better understand of TB processes and outcomes for all involved. 
Furthermore, statistical outcomes suggest and equality for completion of treatment which 
encourages all ethnic/racial groups that no group is at a higher risk for not completing therapy 
over the other. More importantly, these data suggest that the public health care system work, as 
well as private provider management of TB are consistent on a national basis. This information is 
very useful when marketing testing and treatment interventions to high-risk population such as 





             
A positive change marketing strategy for the future could include: any persons that enters 
treatment with no other significant medical complications and eligible to complete therapy have 
11.4 times the odds of completing therapy within 12 months regardless of age, gender, and race. 
In addition, person that are not eligible to complete have a 92.3 percent less chance of 
completing therapy within 12 months. The odds ratios described in this study may encourages 
practitioners to advocate to persons with non-complicated TB to complete therapy. Practitioners 
could also consider strongly encouraging complicated cases to remain in therapy until complete 
because they are at the highest odds for not completing treatment.  
Methodological and theoretical frameworks for advanced binomial logistic regression 
and SDOH are appropriate foundations for this study. Statistical methods for the analysis of 
dichotomous dependent and independent variables described the relationships required to 
identify significant correlations (Field, 2009). Each outcome in the final analysis described 
associations which were displayed as EXP (B) odds ratios. Validation of stated methods and 
statistical model provides the best foundation for peer-reviews, evaluation of data, and 
acceptance among practitioners. Future projects should include the theoretical framework 
outlined in this study to continue the process of understanding characteristics of completion of 
therapy. 
Conclusion 
In conclusion, the developmental research outlined in this project is intended to help 
public health practitioners and health care providers understanding characteristics of completion 
of therapy for U.S.-born TB/HIV cases with co-infection. The overarching theme of the 
investigation was highlight treatment outcomes as a baseline performance indicator to see how 
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well programs have managed TB over time in terms of treatment completion. The analysis 
described in the project will hopefully spark an interest in public health research that expands 
completion of therapy and reason therapy stopped outcomes across all populations including 
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